0001104659-21-057746.txt : 20210429 0001104659-21-057746.hdr.sgml : 20210429 20210429170754 ACCESSION NUMBER: 0001104659-21-057746 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210429 DATE AS OF CHANGE: 20210429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ZYNEX INC CENTRAL INDEX KEY: 0000846475 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 870403828 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38804 FILM NUMBER: 21871908 BUSINESS ADDRESS: STREET 1: 9555 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (303) 867-3904 MAIL ADDRESS: STREET 1: 9555 MAROON CIRCLE CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20050812 FORMER COMPANY: FORMER CONFORMED NAME: ZYNEX MEDICAL HOLDINGS INC DATE OF NAME CHANGE: 20040120 FORMER COMPANY: FORMER CONFORMED NAME: FOX RIVER HOLDINGS INC DATE OF NAME CHANGE: 20031126 10-Q 1 zyxi-20210331x10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)


	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2021


	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-38804

Zynex, Inc.

(Exact name of registrant as specified in its charter)

NEVADA		90-0275169
(State or other jurisdiction of		(IRS Employer
incorporation or organization)		Identification No.)

9555 Maroon Cir.
Englewood, CO		80112
(Address of principal executive offices)		(Zip Code)

(303) 703-4906

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☒	Smaller reporting company	☒

		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ⌧

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


Class		Shares Outstanding as of April 28, 2021
Common Stock, par value $0.001		34,846,656

Table of Contents

ZYNEX, INC. AND SUBSIDIARIES

INDEX TO FORM 10-Q


		Page
PART I—FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3

	Consolidated Balance Sheets as of March 31, 2021 (unaudited) and December 31, 2020	3

	Unaudited Consolidated Statements of Operations for the three months ended March 31, 2021 and 2020	4

	Unaudited Consolidated Statements of Cash Flows for the three months ended March 31, 2021 and 2020	5

	Unaudited Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2021 and 2020	6

	Unaudited Notes to Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24

Item 4.	Controls and Procedures	24

PART II—OTHER INFORMATION		25

Item 1.	Legal Proceedings	25

Item 1A.	Risk Factors	25

Item 2.	Unregistered Sales of Equity Securities And Use of Proceeds	25

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	26

SIGNATURES		27

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

ZYNEX, INC.

CONSOLIDATED BALANCE SHEETS

(AMOUNTS IN THOUSANDS, EXCEPT NUMBER OF SHARES)

(unaudited)


	March 31,		December 31,
	2021		2020
ASSETS
Current assets:
Cash	$	33,439	$	39,173
Accounts receivable, net		14,874		13,837
Inventory, net		10,957		8,635
Prepaid expenses and other		1,559		1,378
Total current assets		60,829		63,023

Property and equipment, net		2,299		1,925
Operating lease asset		5,380		5,993
Finance lease asset		457		321
Deposits		340		347
Deferred income taxes		931		566
Total assets	$	70,236	$	72,175

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable and accrued expenses		3,338		4,717
Operating lease liability		2,043		2,051
Finance lease liability		104		77
Income taxes payable		266		280
Accrued payroll and related taxes		3,564		2,992
Total current liabilities		9,315		10,117
Long-term liabilities:
Operating lease liability		4,371		4,920
Finance lease liability		397		283
Total liabilities		14,083		15,320

Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and December 31, 2020		—		—
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,143,761 issued and 34,849,790 outstanding as of March 31, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020		37		36
Additional paid-in capital		37,313		37,235
Treasury stock 1,076,220 shares, at March 31, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost		(3,921)		(3,846)
Retained earnings		22,724		23,430
Total stockholders' equity		56,153		56,855
Total liabilities and stockholders' equity	$	70,236	$	72,175

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF INCOME

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

(unaudited)


	For the Three Months Ended March 31,
	2021		2020
NET REVENUE
Devices	$	6,365	$	3,444
Supplies		17,762		11,784
Total net revenue		24,127		15,228

COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies		5,886		3,401
Sales and marketing		13,827		5,584
General and administrative		5,495		3,785
Total costs of revenue and operating expenses		25,208		12,770

Income/(loss) from operations		(1,081)		2,458

Other expense
Interest expense		(9)		(4)
Other expense, net		(9)		(4)

Income/(loss) from operations before income taxes		(1,090)		2,454
Income tax benefit		(384)		(483)
Net Income/(Loss)	$	(706)	$	2,937

Net income/(loss) per share:
Basic	$	(0.02)	$	0.09

Diluted	$	(0.02)	$	0.09

Weighted average basic shares outstanding		34,837		32,913
Weighted average diluted shares outstanding		34,837		34,204

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS IN THOUSANDS)

(unaudited)


	For the Three Months Ended March 31,
	2021		2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	$	(706)	$	2,937
Adjustments to reconcile net income/(loss) to net cash provided by operating activities:
Depreciation		487		252
Non-cash reserve charges		2		249
Stock-based compensation		108		497
Non-cash lease expense		55		(10)
Provision for deferred income taxes		(378)		(473)
Change in operating assets and liabilities:
Accounts receivable		(1,037)		(716)
Prepaid and other assets		(182)		(819)
Accounts payable and other accrued expenses		(798)		162
Inventory		(2,863)		(1,501)
Deposits		7		54
Net cash provided by/(used in) operating activities		(5,305)		632

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(299)		(297)
Net cash used in investing activities		(299)		(297)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations		(23)		(11)
Purchase of treasury stock		(75)		—
Proceeds from the issuance of common stock on stock-based compensation awards		27		221
Taxes withheld and paid on employees' equity awards		(59)
Net cash (used in)/provided by financing activities		(130)		210
Net increase/(decrease) in cash		(5,734)		545
Cash at beginning of period		39,173		14,040
Cash at end of period	$	33,439	$	14,585

Supplemental disclosure of cash flow information:
Cash paid for interest	$	(9)	$	(4)
Cash paid for rent	$	(521)	$	(328)
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities	$	162	$	1,433
Inventory transferred to property and equipment under lease	$	473	$	187
Inventory transferred to property and equipment as demo devices	$	67	$	—

The accompanying notes are an integral part of these consolidated financial statements

Table of Contents

ZYNEX, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(AMOUNTS IN THOUSANDS, EXCEPT SHARE DATA)

(unaudited)


				Additional								Total
	Common Stock			Paid-in		Treasury		Retained		Non-Controlling		Stockholders’
	Shares	Amount		Capital		Stock		Earnings		Interest		Equity
Balance, December 31, 2019	32,791,665	$	34	$	9,198	$	(3,846)	$	14,356	$	(89)	$	19,653
Exercised and vested stock-based awards	385,917		—		221		—		—		—		221
Stock-based compensation expense	—		—		497		—		—		—		497
Net income	—		—		—		—		2,937		—		2,937
Balance at March 31, 2020	33,177,582	$	34	$	9,916	$	(3,846)	$	17,293	$	(89)	$	23,308


					Additional								Total
	Common Stock				Paid-in		Treasury		Retained		Non-Controlling		Stockholders’
	Shares		Amount		Capital		Stock		Earnings		Interest		Equity
Balance, December 31, 2020		34,791,931	$	36	$	37,235	$	(3,846)	$	23,430	$	—	$	56,855
Exercised and vested stock-based awards		57,769		1		29		—		—		—		30
Stock-based compensation expense		—		—		108		—		—		—		108
Shares of common stock withheld to pay taxes on employees' equity awards		(3,758)		—		(59)		—		—		—		(59)
Warrants exercised		8,848		—		—		—		—		—		—
Treasury stock		(5,000)		—		—		(75)		—		—		(75)
Net income		—		—		—		—		(706)		—		(706)
Balance at March 31, 2021		34,849,790	$	37	$	37,313	$	(3,921)	$	22,724	$	—	$	56,153

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(1) BASIS OF PRESENTATION

Organization

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate in one primary business segment, medical devices which include electrotherapy and pain management products. As of March 31, 2021, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device which received approval by the U.S. Food and Drug Administration (“FDA”) during 2020 and is still awaiting CE Marking in Europe; therefore, ZMS has achieved no revenues to date. Its inactive subsidiaries include Zynex Europe, Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly-owned Colorado corporation) and Pharmazy, Inc. (“Pharmazy”), which was incorporated in June 2015 as a wholly-owned Colorado corporation. The Company’s compound pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

Nature of Business

The Company designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (“IFC”), neuromuscular electrical stimulation (“NMES”) and transcutaneous electrical nerve stimulation (“TENS”). All our medical devices are designed to be patient friendly and designed for home use. Our devices are small, portable, battery operated and include an electrical pulse generator which is connected to the body via electrodes. All of our medical devices are marketed in the U.S. and are subject to FDA regulation and approval. Our products require a physician’s prescription before they can be dispensed in the U.S. Our primary product is the NexWave device. The NexWave is marketed to physicians and therapists by our field sales representatives. The NexWave requires consumable supplies, such as electrodes and batteries, which are shipped to patients on a recurring monthly basis, as needed.

During the three months ended March 31, 2021 and 2020, the Company generated all of its revenue in North America from sales and supplies of its devices to patients and health care providers.

Unaudited Consolidated Financial Statements

The unaudited consolidated financial statements included herein have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures included herein are adequate to make the information presented not misleading. A description of the Company’s accounting policies and other financial information is included in the audited consolidated financial statements as filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Amounts as of December 31, 2020, are derived from those audited consolidated financial statements. These interim consolidated financial statements should be read in conjunction with the annual audited financial statements, accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments necessary to present fairly the financial position of the Company as of March 31, 2021 and the results of its operations and its cash flows for the periods presented. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results that may be achieved for a full fiscal year and cannot be used to indicate financial performance for the entire year.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

During 2020, the Company revised its cost center allocations to better align with its business operations. As a result, reclassifications between general and administrative and selling and marketing expenses have been made to the three months ended March 31, 2020 financial statements to conform to the consolidated 2021 financial statement presentation. These reclassifications had no effect on net earnings, retained earnings or cash flows as previously reported.

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant management estimates used in the preparation of the accompanying consolidated financial statements are associated with the allowance for billing adjustments and uncollectible accounts receivable, the reserve for obsolete and damaged inventory, stock-based compensation, and valuation of long-lived assets and realizability of deferred tax assets.

Leases

The Company determines if an arrangement is a lease at inception or modification of a contract.

The Company recognizes finance and operating lease right-of-use assets and liabilities at the lease commencement date based on the estimated present value of the remaining lease payments over the lease term. For our finance leases, the Company uses the implicit rate to determine the present value of future lease payments. For our operating leases that do not provide an implicit rate, the Company uses incremental borrowing rates to determine the present value of future lease payments. The Company includes options to extend or terminate a lease in the lease term when it is reasonably certain to exercise such options. The Company recognizes leases with an initial term of 12 months or less as lease expense over the lease term and those leases are not recorded on our Consolidated Balance Sheets. For additional information on our leases where the Company is the lessee, see Note 7- Leases.

A significant portion of our device revenue is derived from patients who obtain our devices under month-to-month lease arrangements where the Company is the lessor. Revenue related to devices on lease is recognized in accordance with ASC 842, Leases. Using the guidance in ASC 842, we concluded our transactions should be accounted for as operating leases based on the following criteria below:

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

The lease term is month to month, which does not meet the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease.

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Lease commencement occurs upon delivery of the device to the patient. The Company retains title to the leased device and those devices are classified as property and equipment on the balance sheet. Since our leases are month-to-month and can be returned by the patient at any time, revenue is recognized monthly for the duration of the period in which the patient retains the device.

Accounts Receivable, Net

The Company’s accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the Company’s devices, related supplies or complimentary products. In conjunction with fulfilling the Company’s obligation to deliver a product, the Company invoices the patient’s third-party payor or the patient. Billing adjustments represent the difference between the list price and the reimbursement rates set by third-party payors, including Medicare, commercial payors and amounts billed directly to the patient. Specific amounts, if uncollected over a period of time, may be written-off after several appeals, which in some cases may take longer than twelve months. Substantially all of the Company’s receivables are due from patients with commercial or government health plans and workers compensation claims with a small portion related to private pay individuals, attorney and auto claims.

Revenue Recognition

Revenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to our patient.

Sales of our devices and supplies are primarily made with, and shipped directly to the patient with a small amount of revenue generated from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended March 31,
	2021		2020
Device revenue
Purchased	$	2,332	$	1,280
Leased		4,033		2,164
Total Device revenue		6,365		3,444

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which the difference is identified. Historically these differences have been immaterial and the Company has not had a significant reversal of revenue from prior periods.

A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

Stock-based Compensation

The Company accounts for stock-based compensation through recognition of the cost of employee services received in exchange for an award of equity instruments, which is measured based on the grant date fair value of the award that is ultimately expected to vest during the period. The stock-based compensation expenses are recognized over the period during which an employee is required to provide service in exchange for the award (the requisite service period, which in the Company’s case is the same as the vesting period). For awards subject to the achievement of performance metrics, stock-based compensation expense is recognized when it becomes probable that the performance conditions will be achieved over the respective performance period.

Fair Value of Financial Instruments

The Company’s financial instruments include cash, accounts receivable, accounts payable, and accrued liabilities, for which current carrying amounts approximate fair value due to their short-term nature. Financial instruments also included our operating and finance lease obligations, the carrying value of which approximates fair value because the interest rates on the outstanding borrowings are at rates that approximate market rates for borrowings with similar terms and average maturities.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Inventory, Net

Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory (in thousands):


	March 31, 2021		December 31, 2020

Raw Materials	$	4,102	$	3,213
Work-in-process		390		1,455
Finished Goods		6,617		4,119
	$	11,109	$	8,787
Less: reserve		(152)		(152)
	$	10,957	$	8,635

The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

Segment Information

We define operating segments as components of our enterprise for which separate financial information is reviewed regularly by the chief operating decision-makers to evaluate performance and to make operating decisions. We have identified our Chief Executive Officer, Chief Financial Officer, and Chief Operating Officer as our chief operating decision-makers (“CODM”).

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

We record deferred tax assets and liabilities for the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carry-forwards. We measure deferred tax assets and liabilities using enacted tax rates expected to be applied to taxable income in the years in which those temporary differences are expected to be recovered or settled. We reduce deferred tax assets by a valuation allowance if, based on available evidence, it is more likely than not that these benefits will not be realized.

We recognize tax benefits from uncertain tax positions if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Recent Accounting Pronouncements

In June 2016, FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) ("ASU 2016-13"), Measurement of Credit Losses on Financial Instruments. The standard significantly changes how entities will measure credit losses for most financial assets and certain other instruments that aren't measured at fair value through net income. The standard will replace today's "incurred loss" approach with an "expected loss" model for instruments measured at amortized cost. For available-for-sale debt securities, entities will be required to record allowances rather than reduce the carrying amount, as they do today under the other-than-temporary impairment model. It also simplifies the accounting model for purchased credit-impaired debt securities and loans. This ASU is effective for annual periods beginning after December 15, 2022, and interim periods therein for smaller reporting companies. Early adoption is permitted for annual periods beginning after December 15, 2018, and interim periods therein. The Company is currently evaluating the impact that the adoption of ASU 2016-13 will have on our financial condition, results of operations and cash flows.

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a material impact on the Company’s consolidated financial statements.

(2) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):


	March 31, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,196	$	2,362
Assembly equipment		151		143
Vehicles		198		198
Leasehold improvements		1,013		559
Sales Rep demo units		313		361
Leased devices		1,086		809
	$	4,957	$	4,432
Less accumulated depreciation		(2,658)		(2,507)
	$	2,299	$	1,925

Total depreciation expense related to our property and equipment was $0.1 million for each of the three months ended March 31, 2021 and 2020.

Total depreciation expense related to devices out on lease was $0.2 million for each of the three months ended March 31, 2021 and 2020. Depreciation on leased units is reflected on the income statement as cost of revenue.

Total depreciation expense related to demo unit devices out with sales representatives was $0.1 million and nil for the three months ended March 31, 2021 and 2020, respectively. Deprecation on demo units is reflected on the income statement as sales and marketing expense.

The Company monitors devices out on lease for potential loss and places an estimated reserve on the net book value based on an analysis of the number of units of which are still with patients for which the Company cannot determine the current status.

The Company monitors demo devices for potential losses and places an estimated reserve on the net book value based on an analysis of terminated territory managers that have not yet returned their units

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(3) EARNINGS PER SHARE

Basic earnings/(loss) per share are computed by dividing net income by the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted-average number of common shares outstanding and the number of dilutive potential common share equivalents during the period, calculated using the treasury-stock method for outstanding stock options. In periods of losses, diluted loss per share is computed on the same basis as basic loss per share as the inclusion of any other potential common shares outstanding would be anti-dilutive.

The calculation of basic and diluted earnings per share for the three months ended March 31, 2021and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended March 31,
	2021		2020
Basic earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Basic weighted-average shares outstanding		34,837		32,913

Basic earnings per share	$	(0.02)	$	0.09

Diluted earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Weighted-average shares outstanding		34,837		32,913
Effect of dilutive securities - options and restricted stock		—		1,291
Diluted weighted-average shares outstanding		34,837		34,204

Diluted earnings per share	$	(0.02)	$	0.09

For the three months ended March 31, 2021 and 2020, 1.1 million and 0.3 million shares of common stock were excluded from the dilutive stock calculation because their effect would have been anti-dilutive.

(4) STOCK-BASED COMPENSATION PLANS

In June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5,000,000 shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon vesting and are not included in outstanding shares until such vesting and issuance occurs.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

During the three months ended March 31, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended March 31, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At March 31, 2021, the company had 0.8 million stock options outstanding and 0.6 million exercisable under the following plans:


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	296		296
Equity Compensation Plans not approved by Shareholders	38		25
2017 Stock Option Plan	490		274
Total	824	$	595

During the three months ended March 31, 2021, 65,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan. During the three months ended March 31, 2020, 165,000 shares of restricted stock were granted. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock is typically released quarterly over three years for the Board of Directors and annually or quarterly over four years for management.

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:


	For the Three Months Ended March 31,
	2021		2020
Cost of Revenue	$	15	$	6
Sales and marketing expense		15		29
General, and administrative		78		462
Total stock based compensation expense	$	108	$	497

The Company received proceeds of $27,000 and $0.2 million related to option exercises during the three months ended March 31, 2021 and 2020, respectively.

The Company used the Black-Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the three months ended March 31, 2021 and March 31, 2020.


	For the Three Months
	Ended March 31,
	2021		2020
Expected term (years)	—		6.79
Risk-free interest rate	—	%	1.59	%
Expected volatility	—	%	116.76	%
Expected dividend yield	—	%	—	%

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Granted	—	$	—
Forfeited	(174)	$	7.65
Exercised	(8)	$	3.12
Outstanding at March 31, 2021	824	$	2.07	5.79	$	10,873

Exercisable at March 31, 2021	595	$	1.73	5.23	$	8,061

A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		65
Forfeited		(66)
Vested		(49)
Granted but not vested at March 31, 2021		218

As of March 31, 2021, the Company had approximately $3.5 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.3 years.

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

On March 8, 2021, our Board of Directors approved a program to repurchase up to $10.0 million of our common stock at prevailing market prices either in the open market or through privately negotiated transactions through September 8, 2021. From the inception of the plan through March 31, 2021, the Company purchased 5,000 shares of our common stock for $0.1 million or an average price of $14.79 per share.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

Warrants

A summary of stock warrant activity for the three months ended March 31, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.52		192
Forfeited	—	$	—
Outstanding and Exercisable at March 31, 2021	90	$	2.64		3.52	$	1,137

(6) INCOME TAXES

The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, primarily related to excess tax benefits on stock option exercises. For the three months ended March 31, 2021 discrete items adjusted were $0.4 million. At March 31, 2021 the Company is currently estimating an annual effective tax rate of approximately 25.2%. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to various factors.

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 35% for the three months ended March 31, 2021. Discrete items recognized during the three months ended March 31, 2021 and 2020, resulted in a tax benefit of approximately $0.1 million and $1.1 million, respectively. The Company recorded an income tax benefit of $0.4 million and $0.5 million for the three months ended March 31, 2021 and 2020, respectively.

No taxes were paid during the three months ended March 31, 2021 and 2020.

(7) LEASES

The Company has five operating leases; four pertaining to its corporate headquarters and one for its warehouse facility located in Englewood, CO. Details of each lease are as follows:

●

The Company entered into a sublease agreement on October 20, 2017 with CSG Systems Inc. for approximately 41,715 square feet. The term of the sublease runs through June 30, 2023, with an option to extend for an additional two years through June 30, 2025. During the first year of the sublease, the rent per square foot is $7.50, which increased to $19.75 during the second year of the sublease and each year thereafter increasing by an additional $1 per square foot. The Company has not yet determined whether it is reasonably certain to exercise its renewal option and has therefore only considered the initial term when determining the lease liability and lease asset. The Company is also obligated to pay its proportionate share of building operating expenses. The sub-landlord agreed to contribute approximately $0.2 million toward tenant improvements which was accounted for as a reduction of the operating lease asset and subsequently treated as a reduction of rent expense over the term of the lease. Upon lease commencement, the Company recorded an

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

operating lease liability of $3.9 million and a corresponding right-of-use asset for $3.6 million. The remaining lease term was 2.3 years at March 31, 2021.

●

The Company entered into an amendment to its sublease agreement, above, on March 11, 2019 for an additional 21,420 square feet of office space. The term of the sublease for the additional space began on June 1, 2019 and runs through June 30, 2023, with an option to extend the term for an additional two years through June 30, 2025. During the first seven months of the Amendment to the Sublease, the rent per square foot was $10.00, which increased to $20.75 from January 1, 2020 through October 31, 2020. For annual periods beginning November 1, 2020, the price per square foot increases by an additional $1 per square foot. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.6 million each. The remaining lease term was 2.3 years at March 31, 2021.

●

The Company entered into an amendment to its sublease agreement, above, on January 3, 2020 for an additional 22,546 square feet of office space. The term of the sublease began on March 9, 2020 and will run through June 30, 2025. From the commencement date through October 31, 2020, the rent per square foot is $13.00, increasing to $21.75 per square foot from November 1, 2020 through October 31, 2021. The price per square foot increases by an additional $1 annually beginning November 1, 2021. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.4 million each. The remaining lease term was 2.3 years at March 31, 2021.

●

The Company entered into a lease agreement on September 17, 2020 with GIG CW Compark, LLC for approximately 50,488 square feet. The term of the lease began on January 5, 2021 and will run through June 5, 2026. The lease includes an option to extend the lease for one additional five year period. Base rent began at $9.40 per square feet increasing each year thereafter by an additional $0.30 per square foot. The Company has not yet determined whether or not it is reasonably certain to exercise its renewal option. The Company is also obligated to pay its proportional share of building operating expenses. The landlord agreed to contribute approximately $0.4 million toward tenant improvements. The Company determined that lease commencement occurred earlier than lease inception on January 5, 2021 as the Company began making significant tenant improvements and storing inventory at this location during December 2020. Upon lease commencement, the Company recorded an operating lease liability of $2.4 million and a corresponding right-of-use asset of $2.1 million. The remaining lease term was 5.2 years at March 31, 2021.

●

Subsequent to March 31, 2021, the Company entered into a sublease agreement on April 9, 2021 with Cognizant Trizetto Software Group, Inc. for approximately 166,912 square feet of office space as its new corporate headquarters. The term of the sublease will begin upon move in at some point during second quarter and will run through April 29, 2028. The Company is entitled to rent credits equal to twenty-one months of base rent at the initial rate. During the first thirty-three months of the sublease, the rent per square foot is $26.50. The price per square foot increases by an additional $0.50 during each subsequent twelve-month period of the sublease. The Company estimates that it will record a right-of-use asset and liability of $13.4 million each upon lease commencement.

The Company has five finance leases for office equipment as follows:

●

The Company entered into an equipment lease on September 20, 2019 with Konica Minolta Premier Finance for a copier/printer and related software located at its corporate offices. The term of the equipment lease agreement is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 3.6 years at March 31, 2021.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

●

The Company entered into an equipment lease on March 3, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its corporate offices. The term of the equipment lease agreement is 4 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 3.0 years at March 31, 2021.

●

The Company entered into an equipment lease on November 25, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 4.7 years at March 31, 2021.

The Company entered into an equipment lease on December 14, 2020 with Konica Minolta Premier Finance for mail solution and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5.3 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 5.3 years at March 31, 2021.

●

The Company entered into an equipment lease on November 3, 2020 with Altitude Leasing for a baler located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 3 years with no option to purchase the equipment at the end of the lease. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $8,000 each. The remaining lease term was 2.8 years at March 31, 2021.

Table of Contents

ZYNEX, INC.

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

The Company’s operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s incremental borrowing rate was determined to be 4.0% for its operating lease liabilities. The Company’s equipment lease agreements have implicit rates from 8.3% to 20.7%, which were used to measure its finance lease liability.


	Operating lease liability		Financing lease liability
April 1, 2021 through December 31, 2021		1,768		110
2022		2,447		147
2023		1,514		147
2024		512		116
2025		528		73
2026		223		19
Total undiscounted future minimum lease payments		6,992		612
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(578)		(111)
Total lease liabilities	$	6,414	$	501

Operating lease costs were $0.6 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively. For the three months ended March 31, 2021, $0.2 million of operating lease costs incurred primarily at our manufacturing and warehouse facility were included in cost of sales and $0.4 million were included in general and administrative expenses on the consolidated statement of operations. All operating lease costs for the three months ended March 31, 2020 were included in general and administrative expenses on the consolidated statement of operations.

(8) CONCENTRATIONS

For the three months ended March 31, 2021, the Company sourced approximately 32% of the components for its electrotherapy products from two significant vendors (defined as supplying at least 10%). For the three months ended March 31, 2020 the company sourced approximately 40% of components from two significant vendors.

Management believes that its relationships with suppliers are good; however, if the relationships were to be replaced, there may be a short-term disruption to operations, a period of time in which products may not be available and additional expenses may be incurred.

At March 31, 2021, the Company had receivables from two third-party payers that made up approximately 37% of the net accounts receivable balance. At December 31, 2020, the Company had receivables from one third-party payer that made up approximately 26% of the net accounts receivable balance.

(9) LITIGATION

From time to time, the Company may become party to litigation and other claims in the ordinary course of business. To the extent that such claims and litigation arise, management would accrue the estimated exposure for such events when losses are determined to be both probable and estimable.

The Company is currently not a party to any material pending legal proceedings.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Notice Regarding Forward-Looking Statements

This quarterly report contains statements that are forward-looking, such as statements relating to plans for future organic growth and other business development activities, as well as the impact of reimbursement trends, other capital spending and financing sources. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of the Company. These risks include the ability to engage effective sales representatives, the need to obtain U.S. Food and Drug Administration (“FDA”) clearance and Certificate European (“CE”) marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, our dependence on the reimbursement from insurance companies for products sold or leased to our customers, acceptance of our products by health insurance providers for reimbursement, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third-party manufacturers to produce key components of our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on our business, and other risks described herein and in our Annual Report on Form 10-K for the year ended December 31, 2020.

These interim financial statements and the information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the annual audited consolidated financial statements, and notes to consolidated financial statements, included in the Company’s 2020 Annual Report on Form 10-K and subsequently filed reports, which have previously been filed with the Securities and Exchange Commission.

General

Zynex, Inc. (a Nevada corporation) has its headquarters in Englewood, Colorado. We operate in one primary business segment, medical devices which include electrotherapy and pain management products. As of December 31, 2020, the Company’s only active subsidiary is Zynex Medical, Inc. (“ZMI,” a wholly-owned Colorado corporation) through which the Company conducts most of its operations. Zynex Monitoring Solutions, Inc. (“ZMS,” a wholly-owned Colorado corporation) has developed a blood volume monitoring device which received approval by the U.S. Food and Drug Administration (“FDA”) during 2020 and is still awaiting CE Marking in Europe; therefore, ZMS has achieved no revenues to date. Its inactive subsidiaries include Zynex Europe, Zynex NeuroDiagnostics, Inc. (“ZND,” a wholly-owned Colorado corporation) and Pharmazy, Inc. (“Pharmazy”), which was incorporated in June 2015 as a wholly-owned Colorado corporation. The Company’s compound pharmacy operated as a division of ZMI dba as Pharmazy through January 2016.

The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

RESULTS OF OPERATIONS

Summary

Net revenue was $24.1 million and $15.2 million for the three months ended March 31, 2021 and 2020, respectively. Net revenue increased 58% for the three-month period ended March 31, 2021. The Company had a net loss of $0.7 million during the three months ended March 31, 2021 as compared with net income of $2.9 million during the three months ended March 31, 2020. Cash flows used in operating activities were $5.3 million during the three months ended March 31, 2021.Working capital at March 31, 2021 was $51.5 million, a decrease of 3% from $52.9 million as of December 31, 2020.

Table of Contents

Net Revenue

Net revenues are comprised of device and supplies sales, constrained by estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Product device revenue is primarily comprised of sales and rentals of our electrotherapy products and other complimentary products.

Supplies revenue is primarily comprised of sales of our consumable supplies to patients using our electrotherapy products, consisting primarily of surface electrodes and batteries.

Revenue related to both devices and supplies is reported net, after adjustments for estimated third-party payor reimbursement deductions and estimated uncollectible amounts. Estimates for third-party payor reimbursement deductions and uncollectible accounts are adjusted on an ongoing basis in conjunction with the processing of third-party payor insurance claims and other customer collection history. Billing allowance adjustments are common in our industry whereby third-party payors unilaterally reduce the amount they reimburse for our products as compared to the sales price charged by us. These deductions from gross revenue take into account the estimated denials, net of resubmitted billings of claims for products placed with patients which may affect collectability. See our Significant Accounting Policies in Note 1 to the Consolidated Financial Statements for a more complete explanation of our revenue recognition policies.

We occasionally receive, and expect to continue to receive, refund requests from insurance providers relating to specific patients and dates of service. Billing and reimbursement disputes are very common in our industry. These requests are sometimes related to a few patients and other times include a significant number of refund claims in a single request. We review and evaluate these requests and determine if any refund is appropriate. We also review claims that have been resubmitted or where we are pursuing additional reimbursement from that insurance provider. We frequently have significant offsets against such refund requests which may result in amounts that are due to us in excess of the amounts of refunds requested by the insurance providers. Therefore, at the time of receipt of such refund requests we are generally unable to determine if a refund request is valid.

Net revenue increased $8.9 million or 58% to $24.1 million for the three months ended March 31, 2021, from $15.2 million for the same period in 2020. The growth in net revenue is primarily related to the 140% growth in device orders which led to an increased customer base and drove higher sales of consumable supplies.

Device Revenue

Device revenue is related to the sale or lease of our products. Device revenue increased $3.0 million or 85% to $6.4 million for the three months ended March 31, 2021, from $3.4 million for the same period in 2020.The increase in device revenue is primarily related to increased orders which are attributable to the growth of our sales force.

Supplies Revenue

Supplies revenue is related to the sale of supplies, primarily electrodes and batteries, for our products. Supplies revenue increased $6.0 million or 51% to $17.8 million for the three months ended March 31, 2021, from $11.8 million for the same period in 2020.The increase in supplies revenue is primarily related to an increased customer base from increased device sales in 2020 and 2021.

Table of Contents

Operating Expenses

Cost of Revenue – Device and Supply

Cost of Revenue – device and supply consist primarily of device and supply costs, operations labor and overhead, shipping and depreciation. Cost of revenue for the three months ended March 31, 2021 increased 73% to $5.9 million from $3.4 million for the three months ended March 31, 2020. The increase in cost of revenue is primarily due to an increase of 140% in device orders. As a percentage of revenue, cost of revenue – device and supply increased to 24% for the three months ended March 31, 2021 from 22% for the same period in 2020. The increase as a percentage of revenue is due to lower collections from certain commercial insurance payors as well an increase in overhead costs related to the new manufacturing and warehouse facility that the Company began operating out of in January 2021.

Sales and Marketing Expense

Sales and marketing expenses primarily consist of employee related costs, including commissions and other direct costs associated with these personnel including travel expenses and marketing campaign and related expenses. Sales and marketing expense for the three months ended March 31, 2021 increased 148% to $13.8 million from $5.6 million for the three months ended March 31, 2020. The increase in sales and marketing expense is primarily due to the expansion of our sales force and the related costs associated with increased headcount. As a percentage of revenue, sales and marketing expense increased to 57% for the three months ended March 31, 2021 from 37% for the same period in 2020. The increase as a percentage of revenue is primarily due to the increase aforementioned expenses, partially offset by the increase in revenue during the period.

General and Administrative Expense

General and administrative expenses primarily consist of employee related costs, and other direct costs associated with these personnel including facilities and travel expenses and professional fees, depreciation and amortization. General and administrative expense for the three months ended March 31, 2021 increased 45% to $5.5 million from $3.8 million for the three months ended March 31, 2020.The increase in general and administrative expense is primarily due to increased compensation and benefit expense related to headcount growth and increases in rent and facilities expense as we expanded our corporate headquarters during March 2020 as well as leased a new manufacturing and warehouse facility in December 2020. As a percentage of revenue, general and administrative expense decreased to 23% for the three months ended March 31, 2021 from 25% for the same period in 2020. The decrease as a percentage of revenue is primarily due to the increase in revenue during the period, partially offset by the aforementioned expenses.

Income Taxes

The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year. The Company’s effective income tax rate was 35% for the three months ended March 31, 2021. Discrete items, primarily related to excess tax benefits on stock option exercises, of $0.1 million and $1.1 million were recognized as a benefit against income tax expense for the three months ended March 31, 2021 and 2020, respectively. For the three months ended March 31, 2021 the company has an income tax benefit of approximately $0.4 million. For the three months ended March 31, 2020 the company had an income tax benefit of approximately $0.5 million.

LIQUIDITY AND CAPITAL RESOURCES

We have historically financed operations through cash flows from operations, debt and equity transactions. At March 31, 2021, our principal source of liquidity was $33.4 million in cash and $14.9 million in accounts receivable.

Table of Contents

Net cash used in operating activities for the three months ended March 31, 2021 was $5.3 million compared with net cash provided by operating activities of $0.6 million for the three months ended March 31, 2020. The increase in cash used in operating activities for the three months ended March 31, 2021 was primarily due to the significant increase in inventory in 2021 as well as an increase in receivables balances. The increase in inventory is related to our order growth plus increased stockpiles in anticipation of possible supply chain shortages related to the COVID-19 virus.

Net cash used in investing activities for each of the three months ended March 31, 2021 and 2020 was $0.3 million. Cash used in investing activities for both periods was primarily related to office furniture and equipment and leasehold improvements at our new manufacturing and warehouse facility for the three months ended March 31, 2021 and at our corporate headquarters for the three months ended March 31, 2020.

Net cash used in financing activities for the three months ended March 31, 2021 was $0.1 million compared with net cash provided by financing activities of $0.2 million for the same period in 2020. The cash used in financing activities for the three months ended March 31, 2021 was primarily due to treasury stock purchase activity. Cash provided by financing activities for the three months ended March 31, 2020 was primarily due to proceeds from the issuance of common stock upon exercises of stock options.

We believe our cash and cash equivalents, together with anticipated cash flow from operations will be sufficient to meet our working capital, and capital expenditure requirements for at least the next twelve months. In making this assessment, we considered the following:

●

Our cash and cash equivalents balance at March 31, 2021 of $33.4 million;

●

Our working capital balance of $51.5 million; and

●

Our projected income and cash flows for the next 12 months.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America.

Please refer to the “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and Note 2 to the Consolidated Financial Statements located within our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and Exchange Commission on February 25, 2021.

OFF BALANCE SHEET ARRANGEMENTS

The Company had no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to our stockholders.

RISKS AND UNCERTAINTIES

In December 2019, a novel Coronavirus disease (“COVID-19”) was reported and on March 11, 2020, the World Health Organization characterized COVID-19 as a pandemic. While the Company did not incur significant disruptions to its operations during the three months ended March 31, 2021 from COVID-19, it is unable at this time to predict the impact that COVID-19 will have on its business, financial position and operating results in future periods due to numerous uncertainties. The Company has been and continues to closely monitor the impact of the pandemic on all aspects of its business.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

In the ordinary course of business, we are exposed to certain market risks, including changes in interest rates. Uncertainties that are either non-financial or non-quantifiable such as political, economic, tax, other regulatory, or credit risks are not included in the following assessment of market risks.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer (CEO) and chief financial officer (CFO), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of March 31, 2021, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission (SEC), and that such information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Changes in Internal Control Over Financial Reporting

During the three months ended March 31, 2021, there were no changes that materially affected or are reasonably likely to affect our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are not a party to any material pending legal proceedings.

ITEM 1A. RISK FACTORS

As of the filing date of this Quarterly Report on Form 10-Q, there have been no material changes in the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 25, 2021.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Items 2(a) and 2(b) are not applicable.

Issuer Purchases of Equity Securities


	(a)	(b)		(c)	(d)

	Total
	Number of	Average		Total Number of	Approximate Dollar
	Shares	Price Paid		Shares Purchased as Part of	Value (in thousands) of Shares that may
	Purchased	per Share		Publicly Announced Program	yet be Purchased under the Program

March 8 to March 31, 2021	5,000	$	14.79	5,000	$	9,926

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. MINE SAFETY DISCLOSURES

N/A

ITEM 5. OTHER INFORMATION

None

Table of Contents

ITEM 6. EXHIBITS


Exhibit Number		Description

10.1		Sublease Agreement, dated April 8, 2021, by and between Zynex, Inc. and Cognizant Trizetto Software Group, Inc. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K previously filed on April 9, 2021 with the Commission and incorporated herein by reference).

31.1*		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

31.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

32.1*		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.

101.INS*		XBRL Instance Document.

101.SCH*		XBRL Taxonomy Extension Schema Document.

101.CAL*		XBRL Taxonomy Calculation Linkbase Document.

101.LAB*		XBRL Taxonomy Label Linkbase Document.

101.PRE*		XBRL Presentation Linkbase Document.

101.DEF *		XBRL Taxonomy Extension Definition Linkbase Document.

*Filed herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	ZYNEX, INC.

	/s/ Daniel J. Moorhead
Dated: April 29, 2021	Daniel J. Moorhead
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-31.1 2 zyxi-20210331xex31d1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Thomas Sandgaard, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 29, 2021


/s/ Thomas Sandgaard
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

EX-31.2 3 zyxi-20210331xex31d2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, Daniel J. Moorhead, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Zynex, Inc.;

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 29, 2021


/s/ Daniel J. Moorhead
Daniel J. Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer

EX-32.1 4 zyxi-20210331xex32d1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, for the purposes of Section 1350 of Chapter 63 of Title 18 of the United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Zynex, Inc. (“Zynex”), that to his knowledge:

1.This Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of April 29, 2021.


/s/ Thomas Sandgaard
Thomas Sandgaard
Chairman, President, Chief Executive Officer and Principal Executive Officer

EX-32.2 5 zyxi-20210331xex32d2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

1.This Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.The information contained in such Report fairly presents, in all material respects, the financial condition and results of operations of Zynex for the period covered by this Report.

This Certification is executed as of April 29, 2021.


/s/ Daniel J. Moorhead
Daniel J. Moorhead
Chief Financial Officer and Principal Financial and Accounting Officer

The foregoing certifications are not deemed filed with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (Exchange Act), and are not to be incorporated by reference into any filing of Zynex, Inc. under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-101.SCH 6 zyxi-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONSOLIDATED STATEMENTS OF INCOME link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - BASIS OF PRESENTATION - Breakdown of net revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - BASIS OF PRESENTATION - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - EARNINGS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 407010 - Disclosure - LEASES (Details) - Calc 2 link:presentationLink link:calculationLink link:definitionLink 510435 - Statement - LEASES (Details) Alternate 1 link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - STOCK-BASED COMPENSATION PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - BASIS OF PRESENTATION - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - PROPERTY AND EQUIPMENT - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - EARNINGS PER SHARE - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - STOCK-BASED COMPENSATION PLANS - Stock options granted (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) link:presentationLink link:calculationLink link:definitionLink 40406 - Disclosure - STOCK-BASED COMPENSATION PLANS - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - STOCKHOLDERS' EQUITY - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - INCOME TAXES - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - LEASES - Additional information (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - STOCK-BASED COMPENSATION PLANS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - LITIGATION link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - BASIS OF PRESENTATION (Tables) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 zyxi-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 zyxi-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 zyxi-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document Type Document Period End Date Document Quarterly Report Document Transition Report Entity Registrant Name Entity Current Reporting Status Security Exchange Name Title of 12(b) Security Entity Interactive Data Current Entity Small Business Entity Emerging Growth Company Entity Filer Category Entity Shell Company Entity Common Stock, Shares Outstanding Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Central Index Key Amendment Flag Trading Symbol Entity File Number Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number CONSOLIDATED BALANCE SHEETS Statement [Table] Statement [Line Items] Statement Assets [Abstract] ASSETS Assets, Current [Abstract] Current assets: Cash Cash at end of period Cash at beginning of period Cash Accounts Receivable, Net, Current Accounts receivable, net Inventory, Net Inventory, net Inventory, net Prepaid Expense and Other Assets, Current Prepaid expenses and other Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Property and Equipment, Net Operating Lease, Right-of-Use Asset Operating lease asset Operating lease asset Finance Lease, Right-of-Use Asset Financing lease asset Finance lease asset Deposits Assets, Noncurrent Deposits Deferred Tax Assets, Net, Noncurrent Deferred income taxes Assets Total assets Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current [Abstract] Current liabilities: Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued expenses Operating Lease, Liability, Current Operating lease liability Finance Lease, Liability, Current Finance lease liability Accrued Income Taxes, Current Income taxes payable Employee-related Liabilities, Current Accrued payroll and related taxes Liabilities, Current Total current liabilities Liabilities, Other than Long-term Debt, Noncurrent [Abstract] Long-term liabilities: Operating Lease, Liability, Noncurrent Operating lease liability Finance Lease, Liability, Noncurrent Finance lease liability Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and December 31, 2020 Common Stock, Value, Issued Common stock, $0.001 par value; 100,000,000 shares authorized; 36,143,761 issued and 34,849,790 outstanding as of March 31, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020 Additional Paid in Capital, Common Stock Additional paid-in capital Treasury Stock, Value Treasury stock 1,076,220 shares, at March 31, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost Retained Earnings (Accumulated Deficit) Retained earnings Stockholders' Equity Attributable to Parent Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Treasury Stock, Shares CONSOLIDATED STATEMENTS OF INCOME Product and Service [Axis] Products And Services [Domain] Product and Service [Domain] Represent the devices. Devices [Member] Devices [Member] Public Utilities Inventory Supplies [Member] Supplies [Member] Revenues [Abstract] NET REVENUE Revenues Total Device revenue Total net revenue Operating Expenses [Abstract] COSTS OF REVENUE AND OPERATING EXPENSES Cost of Goods and Services Sold Costs of revenue - devices and supplies Selling and Marketing Expense Sales and marketing General and Administrative Expense General and administrative Costs and Expenses Total costs of revenue and operating expenses Operating Income (Loss) Income/(loss) from operations Nonoperating Income (Expense) [Abstract] Other expense Interest Income (Expense), Net Interest expense Nonoperating Income (Expense) Other expense, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income/(loss) from operations before income taxes Income Tax Expense (Benefit) Income tax benefit Income tax benefit Net income available to common stockholders Net Income (Loss) Attributable to Parent Net income available to common stockholders Net Income/(Loss) Net income/(loss) Earnings Per Share, Basic and Diluted [Abstract] Net income/(loss) per share: Earnings Per Share, Basic Basic Basic earnings per share Earnings Per Share, Diluted Diluted earnings per share Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Basic Basic weighted-average shares outstanding Weighted average basic shares outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted average diluted shares outstanding Diluted weighted-average shares outstanding CONSOLIDATED STATEMENTS OF CASH FLOWS Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income/(loss) to net cash provided by operating activities: Depreciation Depreciation Amount of non-cash reserve charges. Non-Cash Reserve Charges Non-cash reserve charges Share-based Compensation Stock-based compensation Amount of Non-cash lease expense. Increase Decrease In Non Cash Lease Expense Non-cash lease expense Deferred Income Tax Expense (Benefit) Provision for deferred income taxes Increase (Decrease) in Operating Capital [Abstract] Change in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaid and other assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and other accrued expenses Increase (Decrease) in Inventories Inventory Increase (Decrease) in Deposit Assets Deposits Net Cash Provided by (Used in) Operating Activities Net cash provided by/(used in) operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Payments to Acquire Property, Plant, and Equipment Purchase of property and equipment Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Finance Lease, Principal Payments Payments on finance lease obligations Payments for Repurchase of Common Stock Purchase of treasury stock Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised Proceeds from the issuance of common stock on stock-based compensation awards Payment, Tax Withholding, Share-based Payment Arrangement Taxes withheld and paid on employees' equity awards Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase/(decrease) in cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash paid for interest Amount paid for rent. Rent Paid Cash paid for rent Noncash Investing and Financing Items [Abstract] Supplemental disclosure of non-cash investing and financing activities: Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets obtained in exchange for new operating lease liabilities The amount of inventory transferred to property and equipment under lease in in noncash investing or financing activities. Inventory Transferred To Property and Equipment Under Lease Inventory transferred to property and equipment under lease Amount of inventory transferred to sales rep demos. Inventory Transferred to Sales Rep Demos Inventory transferred to property and equipment as demo devices CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Shares, Outstanding Balance (in shares) Balance (in shares) Value of stock issued as a result of the exercise and vest of stock-based awards. Stock Issued During Period, Value, Stock Based Awards Exercised and Vested Exercised and vested stock-based awards Number of stock-based awards exercised or vested during the current period. Share-based Compensation Arrangement by Share-based Payment Award, Stock Based Awards, Exercises and Vested in Period Exercised and vested stock-based awards (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Stock-based compensation expense Value of shares withheld to pay tax withholding for share based compensation. Shares With held To Pay Tax Withholding For Share Based Compensation Shares of common stock withheld to pay taxes on employees' equity awards Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Shares of common stock withheld to pay taxes on employees' equity awards (in shares) Stock Issued During Period Shares Stock Warrants Exercised. Stock Issued During Period, Shares, Stock Warrants Exercised Warrants exercised (in shares) Stock Repurchased During Period, Value Treasury stock Stock Repurchased During Period, Value Stock Repurchased During Period, Shares Treasury stock (in shares) Stock Repurchased During Period, Shares Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] BASIS OF PRESENTATION PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] PROPERTY AND EQUIPMENT EARNINGS PER SHARE Earnings Per Share [Text Block] EARNINGS PER SHARE STOCK-BASED COMPENSATION PLANS Disclosure of Compensation Related Costs, Share-based Payments [Text Block] STOCK-BASED COMPENSATION PLANS STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY INCOME TAXES Income Tax Disclosure [Text Block] INCOME TAXES LEASES Leases of Lessee Disclosure [Text Block] LEASES CONCENTRATIONS Concentration Risk Disclosure [Text Block] CONCENTRATIONS LITIGATION Commitments and Contingencies Disclosure [Text Block] LITIGATION Consolidation, Policy [Policy Text Block] Principles of Consolidation Reclassification. Reclassifications Policy Text Block Reclassifications Use of Estimates, Policy [Policy Text Block] Use of Estimates Lessee, Leases [Policy Text Block] Leases Accounts Receivable [Policy Text Block] Accounts Receivable, Net Revenue from Contract with Customer [Policy Text Block] Revenue Recognition Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Stock-based Compensation Fair Value of Financial Instruments, Policy [Policy Text Block] Fair Value of Financial Instruments Inventory, Policy [Policy Text Block] Inventory, Net Segment Reporting, Policy [Policy Text Block] Segment Information Income Tax, Policy [Policy Text Block] Income Taxes New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue Inventory Disclosure [Text Block] Schedule of components of inventory Property, Plant and Equipment [Table Text Block] Schedule of components of property and equipment Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Calculation of Basic and Diluted earnings per share Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost Tabular disclosure for outstanding and exercisable number of stock options. Schedule Of Outstanding And Exercisable Number Of Stock Options [Table Text Block] Schedule of outstanding and exercisable number of options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Summary of fair value of stock options grants Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block] Schedule of share based compensation expenses recorded in the consolidated statement of income Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity under the option plan Nonvested Restricted Stock Shares Activity [Table Text Block] Schedule of restricted stock award activity under all equity compensation plans Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of stock warrant activity Finance Lease, Liability, Maturity [Table Text Block] Schedule of future minimum lease payments under the Company's financing leases and operating lease Schedule of Product Information [Table] Product Information [Line Items] Device revenue Amount of revenue recognized from sale of devices relating to purchased during the year. Revenue From Devices Relating To Purchased Purchased Amount of revenue recognized from sale of devices relating to lease during the year. Revenue From Devices Relating To Leased Leased Inventory, Net [Abstract] Components of inventory Inventory, Raw Materials and Supplies, Gross Raw Materials EX-101.PRE 10 zyxi-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 zyxi-20210331x10q_htm.xml IDEA: XBRL DOCUMENT 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-01 2024-01-31 0000846475 zyxi:OperatingLeasesThreeMember 2020-11-01 2021-10-31 0000846475 zyxi:OperatingLeasesThreeMember 2020-03-09 2020-10-31 0000846475 zyxi:OperatingLeasesTwoMember 2020-01-01 2020-10-31 0000846475 zyxi:OperatingLeasesTwoMember 2019-03-11 2019-09-30 0000846475 zyxi:OperatingLeasesOneMember 2018-10-20 2019-10-19 0000846475 zyxi:OperatingLeasesOneMember 2017-10-20 2018-10-19 0000846475 zyxi:OperatingLeasesThreeMember 2021-11-01 2021-11-01 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 2021-04-09 0000846475 2021-04-09 2021-04-09 0000846475 zyxi:OperatingLeasesTwoMember 2020-11-01 2020-11-01 0000846475 zyxi:OperatingLeasesFourMember 2020-10-01 2020-12-31 0000846475 zyxi:OperatingLeasesOneMember 2019-10-20 2019-10-20 0000846475 us-gaap:CommonStockMember 2021-03-08 0000846475 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000846475 us-gaap:TreasuryStockMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2020-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000846475 us-gaap:TreasuryStockMember 2020-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-03-31 0000846475 us-gaap:NoncontrollingInterestMember 2020-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000846475 us-gaap:TreasuryStockMember 2019-12-31 0000846475 us-gaap:RetainedEarningsMember 2019-12-31 0000846475 us-gaap:NoncontrollingInterestMember 2019-12-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-03-31 0000846475 us-gaap:CommonStockMember 2020-12-31 0000846475 us-gaap:CommonStockMember 2020-03-31 0000846475 us-gaap:CommonStockMember 2019-12-31 0000846475 us-gaap:WarrantMember 2020-01-01 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0000846475 us-gaap:WarrantMember 2021-03-31 0000846475 us-gaap:WarrantMember 2020-12-31 0000846475 us-gaap:EmployeeStockOptionMember 2020-12-31 0000846475 zyxi:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0000846475 zyxi:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0000846475 us-gaap:WarrantMember 2021-01-01 2021-03-31 0000846475 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000846475 zyxi:TwoThousandAndFiveStockOptionPlanMember 2021-03-31 0000846475 zyxi:StockIncentivePlan2017Member 2021-03-31 0000846475 zyxi:EquityCompensationPlansNotApprovedByShareholdersMember 2021-03-31 0000846475 us-gaap:EmployeeStockOptionMember 2021-03-31 0000846475 zyxi:StockIncentivePlan2017Member 2017-06-30 0000846475 us-gaap:RestrictedStockMember 2021-03-31 0000846475 us-gaap:RestrictedStockMember 2020-12-31 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2021-01-01 2021-03-31 0000846475 srt:ManagementMember us-gaap:RestrictedStockMember zyxi:StockIncentivePlan2017Member 2020-01-01 2020-03-31 0000846475 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0000846475 zyxi:DevicesMember 2021-01-01 2021-03-31 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2021-01-01 2021-03-31 0000846475 zyxi:DevicesMember 2020-01-01 2020-03-31 0000846475 us-gaap:PublicUtilitiesInventorySuppliesMember 2020-01-01 2020-03-31 0000846475 zyxi:SalesRepDemoUnitsMember 2021-03-31 0000846475 zyxi:LeasedDevicesMember 2021-03-31 0000846475 us-gaap:VehiclesMember 2021-03-31 0000846475 us-gaap:LeaseholdImprovementsMember 2021-03-31 0000846475 us-gaap:FurnitureAndFixturesMember 2021-03-31 0000846475 us-gaap:EquipmentMember 2021-03-31 0000846475 zyxi:SalesRepDemoUnitsMember 2020-12-31 0000846475 zyxi:LeasedDevicesMember 2020-12-31 0000846475 us-gaap:VehiclesMember 2020-12-31 0000846475 us-gaap:LeaseholdImprovementsMember 2020-12-31 0000846475 us-gaap:FurnitureAndFixturesMember 2020-12-31 0000846475 us-gaap:EquipmentMember 2020-12-31 0000846475 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000846475 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000846475 zyxi:OperatingLeasesFourMember 2020-12-31 0000846475 zyxi:OperatingLeasesTwoMember 2019-06-01 0000846475 zyxi:OperatingLeasesTwoMember 2021-03-31 0000846475 zyxi:OperatingLeasesThreeMember 2021-03-31 0000846475 zyxi:OperatingLeasesOneMember 2021-03-31 0000846475 zyxi:OperatingLeasesFourMember 2021-03-31 0000846475 zyxi:FinanceLeasesOfficeEquipmentTwoMember 2021-03-31 0000846475 zyxi:FinanceLeasesOfficeEquipmentThreeMember 2021-03-31 0000846475 zyxi:FinanceLeasesOfficeEquipmentOneMember 2021-03-31 0000846475 zyxi:FinanceLeasesOfficeEquipmentFourMember 2021-03-31 0000846475 zyxi:FinanceLeasesOfficeEquipmentFiveMember 2021-03-31 0000846475 srt:MinimumMember 2021-03-31 0000846475 srt:MaximumMember 2021-03-31 0000846475 zyxi:OperatingLeasesFiveMember 2021-04-09 0000846475 zyxi:OperatingLeasesFourMember 2020-09-17 0000846475 zyxi:OperatingLeasesThreeMember 2020-01-03 0000846475 zyxi:OperatingLeasesTwoMember 2019-03-11 0000846475 zyxi:OperatingLeasesOneMember 2017-10-20 0000846475 zyxi:FinanceLeasesOfficeEquipmentFourMember 2020-12-14 0000846475 zyxi:FinanceLeasesOfficeEquipmentThreeMember 2020-11-25 0000846475 zyxi:FinanceLeasesOfficeEquipmentFiveMember 2020-11-03 0000846475 zyxi:FinanceLeasesOfficeEquipmentTwoMember 2020-03-03 0000846475 zyxi:FinanceLeasesOfficeEquipmentOneMember 2019-09-20 0000846475 zyxi:EstimatedRateOneMember 2021-01-01 2021-03-31 0000846475 zyxi:SalesRepDemoUnitsMember 2021-01-01 2021-03-31 0000846475 zyxi:Leaseddevices1Member 2021-01-01 2021-03-31 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2021-01-01 2021-03-31 0000846475 zyxi:SalesRepDemoUnitsMember 2020-01-01 2020-03-31 0000846475 zyxi:Leaseddevices1Member 2020-01-01 2020-03-31 0000846475 us-gaap:PropertyPlantAndEquipmentMember 2020-01-01 2020-03-31 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-03-31 0000846475 us-gaap:AccountsReceivableMember 2021-01-01 2021-03-31 0000846475 us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 0000846475 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-03-31 0000846475 2020-03-31 0000846475 2019-12-31 0000846475 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000846475 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0000846475 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0000846475 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000846475 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0000846475 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000846475 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000846475 2020-01-01 2020-03-31 0000846475 2021-03-31 0000846475 2020-12-31 0000846475 2021-04-28 0000846475 2021-01-01 2021-03-31 shares iso4217:USD iso4217:USD shares pure utr:sqft zyxi:segment iso4217:USD utr:sqft zyxi:lease zyxi:item

P0Y

0000846475 --12-31 2021 Q1 ZYNEX INC ZYXI false NV

1600000

200000

1400000

100000

NASDAQ

13400000

100000

200000

8000

10-Q true 2021-03-31 false 001-38804 90-0275169 9555 Maroon Cir. Englewood CO 80112 303 703-4906 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 34846656

33439000

39173000

14874000

13837000

10957000

8635000

1559000

1378000

60829000

63023000

2299000

1925000

5380000

5993000

457000

321000

340000

347000

931000

566000

70236000

72175000

3338000

4717000

2043000

2051000

104000

77000

266000

280000

3564000

2992000

9315000

10117000

4371000

4920000

397000

283000

14083000

15320000

0.001

10000000

0.001

100000000

36143761

34849790

36126698

34791931

37000

36000

37313000

37235000

1076220

1071220

3921000

3846000

22724000

23430000

56153000

56855000

70236000

72175000

6365000

3444000

17762000

11784000

24127000

15228000

5886000

3401000

13827000

5584000

5495000

3785000

25208000

12770000

-1081000

2458000

-9000

-4000

-9000

-4000

-1090000

2454000

-384000

-483000

-706000

2937000

-0.02

0.09

-0.02

0.09

34837000

32913000

34837000

34204000

-706000

2937000

487000

252000

2000 249000

108000

497000

55000 -10000

-378000

-473000

1037000

716000

182000

819000

-798000

162000

2863000

1501000

-7000

-54000

-5305000

632000

299000

297000

-299000

-297000

23000

11000

75000

27000

221000

59000

-130000

210000

-5734000

545000

39173000

14040000

33439000

14585000

9000

4000

521000 328000

162000

1433000

473000 187000 67000 0

32791665

34000

9198000

-3846000

14356000

-89000

19653000

385917 221000 221000

497000

2937000

33177582

34000

9916000

-3846000

17293000

-89000

23308000

34791931

36000

37235000

-3846000

23430000

56855000

57769 1000 29000 30000

108000

-3758

59000 59000 8848

5000

75000

-706000

34849790

37000

37313000

-3921000

22724000

56153000

Accounts Receivable, NetThe Company’s accounts receivables represent unconditional rights to consideration and are generated when a patient receives one of the Company’s devices, related supplies or complimentary products. In conjunction with fulfilling the Company’s obligation to deliver a product, the Company invoices the patient’s third-party payor or the patient. Billing adjustments represent the difference between the list price and the reimbursement rates set by third-party payors, including Medicare, commercial payors and amounts billed directly to the patient. Specific amounts, if uncollected over a period of time, may be written-off after several appeals, which in some cases may take longer than twelve months. Substantially all of the Company’s receivables are due from patients with commercial or government health plans and workers compensation claims with a small portion related to private pay individuals, attorney and auto claims.

Revenue RecognitionRevenue is derived from sales and leases of our electrotherapy devices and sales of related supplies and complimentary products. The Company recognizes revenue when control of the product has been transferred to the patient, in the amount that reflects the consideration the Company expects to receive. In general, revenue from sales of our devices and supplies is recognized once the product is delivered to the patient, which is when control is deemed to have transferred to our patient.Sales of our devices and supplies are primarily made with, and shipped directly to the patient with a small amount of revenue generated from sales to distributors. In the healthcare industry there is often a third party involved that will pay on the patients’ behalf for purchased or leased devices and supplies. The terms of the separate arrangement impact certain aspects of the contracts, with patients covered by third party payors, such as contract type, performance obligations and transaction price, but for purposes of revenue recognition the contract with the customer refers to the arrangement between the Company and the patient. The Company does not have any material deferred revenue in the normal course of business as each performance obligation is met upon delivery of goods to the patient. There are no substantial costs incurred through support or warranty obligations.The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;">Device revenue</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;">Purchased</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"> 2,332</td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;margin:0pt;padding:0pt;"> 1,280</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;">Leased</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,033</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,164</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.01%;margin:0pt;padding:0pt;">Total Device revenue</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,365</td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3,444</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td></tr></table>Revenues are estimated using the portfolio approach by third-party payor type based upon historical rates of collection, aging of receivables, trends in historical reimbursement rates by third-party payor types, and current relationships and experience with the third-party payors, which includes estimated constraints for third-party payor refund requests, deductions and adjustments. Inherent in these estimates is the risk that they will have to be revised as additional information becomes available and constraints are released. Specifically, the complexity of third-party payor billing arrangements and the uncertainty of reimbursement amounts for certain products from third-party payors or unanticipated requirements to refund payments previously received may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party payor reimbursement, it is possible our forecasting model to estimate collections could change, which could have an impact on our results of operations and cash flows. Any differences between estimated and actual collectability are reflected in the period in which the difference is identified. Historically these differences have been immaterial and the Company has not had a significant reversal of revenue from prior periods.A change in the way estimates are determined can result from a number of factors, including changes in the reimbursement policies or practices of third-party payors, or changes in industry rates of reimbursement. The Company monitors the variability and uncertain timing over third-party payor types in our portfolios. If there is a change in our third-party payor mix over time, it could affect our net revenue and related receivables. We believe we have a sufficient history of collection experience to estimate the net collectible amounts by third-party payor type. However, changes to constraints for billing adjustments have historically fluctuated and may continue to fluctuate significantly from quarter to quarter and year to year.

2332000 1280000 4033000 2164000

6365000

3444000

Inventory, NetInventories are stated at the lower of cost and net realizable value. Cost is computed using standard costs, which approximates actual costs on an average cost basis. Following are the components of inventory (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Raw Materials</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 4,102</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 3,213</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Work-in-process</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 390</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 1,455</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Finished Goods</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,617</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,119</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 11,109</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 8,787</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Less: reserve</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,957</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,635</td></tr></table>The Company monitors inventory for turnover and obsolescence and records losses for excess and obsolete inventory, as appropriate. The Company provides reserves for estimated excess and obsolete inventories based upon assumptions about future demand. If future demand is less favorable than currently projected by management, additional inventory write-downs may be required.

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Raw Materials</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 4,102</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 3,213</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Work-in-process</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 390</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 1,455</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Finished Goods</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,617</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 4,119</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;margin:0pt;padding:0pt;"> 11,109</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;margin:0pt;padding:0pt;"> 8,787</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;">Less: reserve</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (152)</td></tr><tr><td style="vertical-align:bottom;width:65.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,957</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,635</td></tr></table>

4102000

3213000

390000

1455000

6617000

4119000

11109000

8787000

152000

10957000

8635000

The components of property and equipment are as follows (in thousands):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">March 31, 2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">December 31, 2020</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Property and equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Office furniture and equipment</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 2,196</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 2,362</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Assembly equipment</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 151</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 143</td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Vehicles</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 198</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 198</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Leasehold improvements</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 1,013</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 559</td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Sales Rep demo units</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 313</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 361</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Leased devices</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,086</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 809</td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;margin:0pt;padding:0pt;"> 4,957</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 4,432</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;">Less accumulated depreciation</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,658)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (2,507)</td></tr><tr><td style="vertical-align:bottom;width:65.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2,299</td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,925</td></tr></table>

2196000

2362000

151000

143000

198000

1013000

559000

313000

361000

1086000

809000

4957000

4432000

2658000

2507000

2299000

1925000

100000

200000

100000

The calculation of basic and diluted earnings per share for the three months ended March 31, 2021and 2020 are as follows (in thousands, except per share data):<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Basic earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Net income available to common stockholders</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> (706)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Basic weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 34,837</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 32,913</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Basic earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.02)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.09</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Diluted earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Net income available to common stockholders</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> (706)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 2,937</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 34,837</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 32,913</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Effect of dilutive securities - options and restricted stock</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,291</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Diluted weighted-average shares outstanding</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 34,837</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;margin:0pt;padding:0pt;"> 34,204</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.89%;margin:0pt;padding:0pt;">Diluted earnings per share</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (0.02)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.89%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 0.09</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr></table>

-706000

2937000

34837000

32913000

-0.02

0.09

-706000

2937000

34837000

32913000

1291000

34837000

34204000

-0.02

0.09

1100000

300000

(4) STOCK-BASED COMPENSATION PLANSIn June 2017, our stockholders approved the 2017 Stock Incentive Plan (the “2017 Stock Plan”) with a maximum of 5,000,000 shares reserved for issuance. Awards permitted under the 2017 Stock Plan include: Stock Options and Restricted Stock. Awards issued under the 2017 Stock Plan are at the discretion of the Board of Directors. As applicable, awards are granted with an exercise price equal to the closing price of our common stock on the date of grant and generally vest over four years. Restricted Stock Awards are issued to the recipient upon vesting and are not included in outstanding shares until such vesting and issuance occurs.During the three months ended March 31, 2021, no stock option awards were granted under the 2017 Stock Plan. During the three months ended March 31, 2020, 14,000 stock option awards were granted under the 2017 Stock Plan. At March 31, 2021, the company had 0.8 million stock options outstanding and 0.6 million exercisable under the following plans:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;">Number of Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;">Number of Options</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Plan Category</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">2005 Stock Option Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 296</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 296</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Equity Compensation Plans not approved by Shareholders</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 38</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 25</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">2017 Stock Option Plan</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 490</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 274</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 824</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 595</td></tr></table>During the three months ended March 31, 2021, 65,000 shares of restricted stock were granted to the Board of Directors and management under the 2017 Stock Plan. During the three months ended March 31, 2020, 165,000 shares of restricted stock were granted. The fair market value of restricted shares for share-based compensation expensing is equal to the closing price of our common stock on the date of grant. The vesting on the Restricted Stock is typically released quarterly over three years for the Board of Directors and annually or quarterly over four years for management.The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Cost of Revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"> 15</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"> 6</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"> 29</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">General, and administrative</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 462</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Total stock based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 497</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr></table>The Company received proceeds of $27,000 and $0.2 million related to option exercises during the three months ended March 31, 2021 and 2020, respectively.The Company used the Black-Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the three months ended March 31, 2021 and March 31, 2020. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"> For the Three Months</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected term (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;">6.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> 1.59</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected volatility</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> 116.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr></table>A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 1,006</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 3.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"> 6.47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 10,483</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> (174)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 7.65</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3.12</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Outstanding at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 824</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,873</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Exercisable at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 595</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.73</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.23</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,061</td></tr></table>A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Number of</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Shares</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 65</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> (66)</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (49)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 218</td></tr></table>As of March 31, 2021, the Company had approximately $3.5 million of unrecognized compensation expense related to stock options and restricted stock awards that will be recognized over a weighted average period of approximately 2.3 years.

5000000000

14000

800000

600000

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;">Outstanding</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;">Exercisable</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;">Number of Options</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;">Number of Options</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Plan Category</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">2005 Stock Option Plan </td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 296</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 296</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Equity Compensation Plans not approved by Shareholders</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 38</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;margin:0pt;padding:0pt;"> 25</td></tr><tr><td style="vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">2017 Stock Option Plan</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 490</td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 274</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.53%;margin:0pt;padding:0pt;">Total</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 824</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 595</td></tr></table>

296000

38000

25000

490000

274000

824000

595000

65000

165000

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.13%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">For the Three Months Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Cost of Revenue </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"> 15</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"> 6</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Sales and marketing expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;margin:0pt;padding:0pt;"> 15</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;margin:0pt;padding:0pt;"> 29</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">General, and administrative</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 78</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 462</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:61.75%;margin:0pt;padding:0pt;">Total stock based compensation expense</td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108</td><td style="vertical-align:bottom;white-space:nowrap;width:2.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:14.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 497</td><td style="vertical-align:bottom;white-space:nowrap;width:0.25%;margin:0pt;padding:0pt;"></td></tr></table>

15000

6000

15000

29000

78000

462000

108000

497000

27000000

200000

The Company used the Black-Scholes option pricing model to determine the fair value of stock option grants, using the following assumptions for the three months ended March 31, 2021 and March 31, 2020. <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.95%;margin:0pt;padding:0pt;"> For the Three Months</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Ended March 31, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:74.34%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2021</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">2020</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected term (years)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;">6.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Risk-free interest rate</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> 1.59</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected volatility</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> 116.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr><tr><td style="vertical-align:top;width:74.34%;margin:0pt;padding:0pt;">Expected dividend yield</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;">%</td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;">%</td></tr></table>

P6Y9M14D

0.0159

1.1676

A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Weighted-</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;">Shares</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Term (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 1,006</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 3.04</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"> 6.47</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"> 10,483</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> (174)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"> 7.65</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Exercised</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3.12</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Outstanding at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 824</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.07</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.79</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,873</td></tr><tr><td style="vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.57%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:52.61%;margin:0pt;padding:0pt;">Exercisable at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 595</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1.73</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5.23</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 8,061</td></tr></table>

1006000

3.04

P6Y5M19D

10483000

174000

7.65

8000

3.12

824000

2.07

P5Y9M14D

10873000

595000

1.73

P5Y2M23D

8061000

A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Number of</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;">Shares</td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 268</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> 65</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Forfeited</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"> (66)</td></tr><tr><td style="vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Vested</td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (49)</td></tr><tr><td style="background-color:#cceeff;vertical-align:top;width:82.31%;margin:0pt;padding:0pt;">Granted but not vested at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 218</td></tr></table>

268000

65000

66000

49000

218000

3500000

P2Y3M18D

10000000.0

5000

100000

14.79

A summary of stock warrant activity for the three months ended March 31, 2021 is presented below:<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Weighted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;">Aggregate</td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;">Number of</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Average</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">Remaining</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;">Intrinsic</td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;">Warrants</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;">Exercise</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;">Contractual</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;margin:0pt;padding:0pt;">Value</td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Price</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Life (Years)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">(in thousands)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;">Outstanding at December 31, 2020</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"> 100</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"> 2.63</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 3.76</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> 1,084</td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;">Granted</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;">Exercised</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.39%;margin:0pt;padding:0pt;"> (10)</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.36%;margin:0pt;padding:0pt;"> 2.50</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;margin:0pt;padding:0pt;"> 3.52</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"> 192</td></tr><tr><td style="vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;">Forfeited</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">$</td><td style="vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> —</td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:57.76%;margin:0pt;padding:0pt;">Outstanding and Exercisable at March 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 90</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 2.64</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 3.52</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,137</td></tr></table>

100000

2.63

P3Y9M3D

1084000

10000

2.50

P3Y6M7D

192000

90000

2.64

P3Y6M7D

1137000

400000

0.252

0.35

100000 1100000

-400000

-500000

(7) LEASESThe Company has five operating leases; four pertaining to its corporate headquarters and one for its warehouse facility located in Englewood, CO. Details of each lease are as follows:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into a sublease agreement on October 20, 2017 with CSG Systems Inc. for approximately 41,715 square feet. The term of the sublease runs through June 30, 2023, with an option to extend for an additional two years through June 30, 2025. During the first year of the sublease, the rent per square foot is $7.50, which increased to $19.75 during the second year of the sublease and each year thereafter increasing by an additional $1 per square foot. The Company has not yet determined whether it is reasonably certain to exercise its renewal option and has therefore only considered the initial term when determining the lease liability and lease asset. The Company is also obligated to pay its proportionate share of building operating expenses. The sub-landlord agreed to contribute approximately $0.2 million toward tenant improvements which was accounted for as a reduction of the operating lease asset and subsequently treated as a reduction of rent expense over the term of the lease. Upon lease commencement, the Company recorded an </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;">operating lease liability of $3.9 million and a corresponding right-of-use asset for $3.6 million. The remaining lease term was 2.3 years at March 31, 2021.</td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an amendment to its sublease agreement, above, on March 11, 2019 for an additional 21,420 square feet of office space. The term of the sublease for the additional space began on June 1, 2019 and runs through June 30, 2023, with an option to extend the term for an additional two years through June 30, 2025. During the first seven months of the Amendment to the Sublease, the rent per square foot was $10.00, which increased to $20.75 from January 1, 2020 through October 31, 2020. For annual periods beginning November 1, 2020, the price per square foot increases by an additional $1 per square foot. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.6 million each. The remaining lease term was 2.3 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an amendment to its sublease agreement, above, on January 3, 2020 for an additional 22,546 square feet of office space. The term of the sublease began on March 9, 2020 and will run through June 30, 2025. From the commencement date through October 31, 2020, the rent per square foot is $13.00, increasing to $21.75 per square foot from November 1, 2020 through October 31, 2021. The price per square foot increases by an additional $1 annually beginning November 1, 2021. Upon lease commencement, the Company recorded an operating lease liability and a corresponding right-of-use asset for $1.4 million each. The remaining lease term was 2.3 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into a lease agreement on September 17, 2020 with GIG CW Compark, LLC for approximately 50,488 square feet. The term of the lease began on January 5, 2021 and will run through June 5, 2026. The lease includes an option to extend the lease for one additional five year period. Base rent began at $9.40 per square feet increasing each year thereafter by an additional $0.30 per square foot. The Company has not yet determined whether or not it is reasonably certain to exercise its renewal option. The Company is also obligated to pay its proportional share of building operating expenses. The landlord agreed to contribute approximately $0.4 million toward tenant improvements. The Company determined that lease commencement occurred earlier than lease inception on January 5, 2021 as the Company began making significant tenant improvements and storing inventory at this location during December 2020. Upon lease commencement, the Company recorded an operating lease liability of $2.4 million and a corresponding right-of-use asset of $2.1 million. The remaining lease term was 5.2 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Subsequent to March 31, 2021, the Company entered into a sublease agreement on April 9, 2021 with Cognizant Trizetto Software Group, Inc. for approximately 166,912 square feet of office space as its new corporate headquarters. The term of the sublease will begin upon move in at some point during second quarter and will run through April 29, 2028. The Company is entitled to rent credits equal to twenty-one months of base rent at the initial rate. During the first thirty-three months of the sublease, the rent per square foot is $26.50. The price per square foot increases by an additional $0.50 during each subsequent twelve-month period of the sublease. The Company estimates that it will record a right-of-use asset and liability of $13.4 million each upon lease commencement.</td></tr></table><div style="margin-top:12pt;"/>The Company has five finance leases for office equipment as follows:<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an equipment lease on September 20, 2019 with Konica Minolta Premier Finance for a copier/printer and related software located at its corporate offices. The term of the equipment lease agreement is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 3.6 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an equipment lease on March 3, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its corporate offices. The term of the equipment lease agreement is 4 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 3.0 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an equipment lease on November 25, 2020 with Konica Minolta Premier Finance for copiers/printers and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.1 million each. The remaining lease term was 4.7 years at March 31, 2021.</td></tr></table><div style="margin-top:12pt;"/><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">·</td><td style="padding:0pt;">The Company entered into an equipment lease on December 14, 2020 with Konica Minolta Premier Finance for mail solution and related software located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 5.3 years with the option to purchase the equipment at the end of the lease. The Company does not expect to exercise the option to purchase the equipment and, accordingly, has not considered the effect of the purchase in the evaluation of the lease asset and liability. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $0.2 million each. The remaining lease term was 5.3 years at March 31, 2021.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">The Company entered into an equipment lease on November 3, 2020 with Altitude Leasing for a baler located at its Grasslands warehouse facility in Colorado. The term of the equipment lease is 3 years with no option to purchase the equipment at the end of the lease. Rent is to be paid monthly at a fixed rate for the term of the equipment lease agreement. Upon lease commencement, the Company recorded a finance lease liability and a corresponding right-of-use asset for $8,000 each. The remaining lease term was 2.8 years at March 31, 2021.</td></tr></table><div style="margin-top:12pt;"/>The Company’s operating leases do not provide an implicit rate, and therefore the Company uses its incremental borrowing rate as the discount rate when measuring the lease liability. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease. The Company’s incremental borrowing rate was determined to be 4.0% for its operating lease liabilities. The Company’s equipment lease agreements have implicit rates from 8.3% to 20.7%, which were used to measure its finance lease liability.<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Operating lease liability</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financing lease liability</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">April 1, 2021 through December 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 1,768</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 110</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 2,447</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 147</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 1,514</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 147</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 512</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 116</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2025</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 528</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 73</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 223</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total undiscounted future minimum lease payments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,992</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 612</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Less: Difference between undiscounted lease payments and discounted lease liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (578)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (111)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,414</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 501</td></tr></table>Operating lease costs were $0.6 million and $0.4 million for the three months ended March 31, 2021 and 2020, respectively. For the three months ended March 31, 2021, $0.2 million of operating lease costs incurred primarily at our manufacturing and warehouse facility were included in cost of sales and $0.4 million were included in general and administrative expenses on the consolidated statement of operations. All operating lease costs for the three months ended March 31, 2020 were included in general and administrative expenses on the consolidated statement of operations.

5 4 1

41715

P2Y

7.50 19.75 1

200000

3900000

3600000

P2Y3M18D

21420

P2Y

10.00 20.75 1

1600000

P2Y3M18D

22546

13.00 21.75 1

1400000

P2Y3M18D

50488

P5Y

9.40 0.30

400000

2400000

2100000

P5Y2M12D

166912

26.50 0.50 0.50

13400000

P5Y

200000

P3Y7M6D

P4Y

100000

P3Y

P5Y

100000

P4Y8M12D

P5Y3M18D

200000

P5Y3M18D

P3Y

8000

P2Y9M18D

0.040

0.083

0.207

<table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Operating lease liability</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">Financing lease liability</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">April 1, 2021 through December 31, 2021</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 1,768</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 110</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2022</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 2,447</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 147</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2023</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 1,514</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 147</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2024</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 512</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 116</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2025</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;margin:0pt;padding:0pt;"> 528</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;margin:0pt;padding:0pt;"> 73</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">2026</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 223</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total undiscounted future minimum lease payments</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,992</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 612</td></tr><tr><td style="vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Less: Difference between undiscounted lease payments and discounted lease liabilities:</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (578)</td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (111)</td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:60.38%;margin:0pt;padding:0pt;">Total lease liabilities</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,414</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;">$</td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:16.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 501</td></tr></table>

1768000

110000

2447000

147000

1514000

147000

512000

116000

528000

73000

223000

19000

6992000

612000

578000

111000

6414000

501000

600000

400000

200000

400000

0.32

0.40

0.37

0.26

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2021	Apr. 28, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	ZYNEX INC
Entity Current Reporting Status	Yes
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, par value $0.001
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,846,656
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000846475
Amendment Flag	false
Trading Symbol	ZYXI
Entity File Number	001-38804
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	90-0275169
Entity Address, Address Line One	9555 Maroon Cir.
Entity Address, City or Town	Englewood
Entity Address, Country	CO
Entity Address, Postal Zip Code	80112
City Area Code	303
Local Phone Number	703-4906

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash	$ 33,439	$ 39,173
Accounts receivable, net	14,874	13,837
Inventory, net	10,957	8,635
Prepaid expenses and other	1,559	1,378
Total current assets	60,829	63,023
Property and equipment, net	2,299	1,925
Operating lease asset	5,380	5,993
Finance lease asset	457	321
Deposits	340	347
Deferred income taxes	931	566
Total assets	70,236	72,175
Current liabilities:
Accounts payable and accrued expenses	3,338	4,717
Operating lease liability	2,043	2,051
Finance lease liability	104	77
Income taxes payable	266	280
Accrued payroll and related taxes	3,564	2,992
Total current liabilities	9,315	10,117
Long-term liabilities:
Operating lease liability	4,371	4,920
Finance lease liability	397	283
Total liabilities	14,083	15,320
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2021 and December 31, 2020	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 36,143,761 issued and 34,849,790 outstanding as of March 31, 2021 and 36,126,698 issued and 34,791,931 outstanding as of December 31, 2020	37	36
Additional paid-in capital	37,313	37,235
Treasury stock 1,076,220 shares, at March 31, 2021 and 1,071,220 shares at December 31, 2020, respectively, at cost	(3,921)	(3,846)
Retained earnings	22,724	23,430
Total stockholders' equity	56,153	56,855
Total liabilities and stockholders' equity	$ 70,236	$ 72,175

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	36,143,761	36,126,698
Common Stock, Shares, Outstanding	34,849,790	34,791,931
Treasury Stock, Shares	1,076,220	1,071,220

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
NET REVENUE
Total net revenue	$ 24,127	$ 15,228
COSTS OF REVENUE AND OPERATING EXPENSES
Costs of revenue - devices and supplies	5,886	3,401
Sales and marketing	13,827	5,584
General and administrative	5,495	3,785
Total costs of revenue and operating expenses	25,208	12,770
Income/(loss) from operations	(1,081)	2,458
Other expense
Interest expense	(9)	(4)
Other expense, net	(9)	(4)
Income/(loss) from operations before income taxes	(1,090)	2,454
Income tax benefit	(384)	(483)
Net Income/(Loss)	$ (706)	$ 2,937
Net income/(loss) per share:
Basic	$ (0.02)	$ 0.09
Diluted	$ (0.02)	$ 0.09
Weighted average basic shares outstanding	34,837	32,913
Weighted average diluted shares outstanding	34,837	34,204
Devices [Member]
NET REVENUE
Total net revenue	$ 6,365	$ 3,444
Supplies [Member]
NET REVENUE
Total net revenue	$ 17,762	$ 11,784

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss)	$ (706)	$ 2,937
Adjustments to reconcile net income/(loss) to net cash provided by operating activities:
Depreciation	487	252
Non-cash reserve charges	2	249
Stock-based compensation	108	497
Non-cash lease expense	55	(10)
Provision for deferred income taxes	(378)	(473)
Change in operating assets and liabilities:
Accounts receivable	(1,037)	(716)
Prepaid and other assets	(182)	(819)
Accounts payable and other accrued expenses	(798)	162
Inventory	(2,863)	(1,501)
Deposits	7	54
Net cash provided by/(used in) operating activities	(5,305)	632
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(299)	(297)
Net cash used in investing activities	(299)	(297)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on finance lease obligations	(23)	(11)
Purchase of treasury stock	(75)	0
Proceeds from the issuance of common stock on stock-based compensation awards	27	221
Taxes withheld and paid on employees' equity awards	(59)
Net cash (used in) provided by financing activities	(130)	210
Net increase/(decrease) in cash	(5,734)	545
Cash at beginning of period	39,173	14,040
Cash at end of period	33,439	14,585
Supplemental disclosure of cash flow information:
Cash paid for interest	(9)	(4)
Cash paid for rent	(521)	(328)
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities	162	1,433
Inventory transferred to property and equipment under lease	473	187
Inventory transferred to property and equipment as demo devices	$ 67	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Non-Controlling Interest [Member]	Total
Balance at Dec. 31, 2019	$ 34	$ 9,198	$ (3,846)	$ 14,356	$ (89)	$ 19,653
Balance (in shares) at Dec. 31, 2019	32,791,665
Exercised and vested stock-based awards		221				221
Exercised and vested stock-based awards (in shares)	385,917
Stock-based compensation expense		497				497
Net income				2,937		2,937
Balance at Mar. 31, 2020	$ 34	9,916	(3,846)	17,293	$ (89)	23,308
Balance (in shares) at Mar. 31, 2020	33,177,582
Balance at Dec. 31, 2020	$ 36	37,235	(3,846)	23,430		56,855
Balance (in shares) at Dec. 31, 2020	34,791,931
Exercised and vested stock-based awards	$ 1	29				30
Exercised and vested stock-based awards (in shares)	57,769
Stock-based compensation expense		108				108
Shares of common stock withheld to pay taxes on employees' equity awards		(59)				(59)
Shares of common stock withheld to pay taxes on employees' equity awards (in shares)	(3,758)
Warrants exercised (in shares)	8,848
Treasury stock	$ (100)		(75)			(75)
Treasury stock (in shares)	(5,000)
Net income				(706)		(706)
Balance at Mar. 31, 2021	$ 37	$ 37,313	$ (3,921)	$ 22,724		$ 56,153
Balance (in shares) at Mar. 31, 2021	34,849,790

XML 18 R7.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION

3 Months Ended

Mar. 31, 2021

BASIS OF PRESENTATION

BASIS OF PRESENTATION

(1) BASIS OF PRESENTATION

Organization

The term “the Company” refers to Zynex, Inc. and its active and inactive subsidiaries.

Nature of Business

During the three months ended March 31, 2021 and 2020, the Company generated all of its revenue in North America from sales and supplies of its devices to patients and health care providers.

Unaudited Consolidated Financial Statements

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

Use of Estimates

Leases

The Company determines if an arrangement is a lease at inception or modification of a contract.

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Accounts Receivable, Net

Revenue Recognition

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended March 31,
	2021		2020
Device revenue
Purchased	$	2,332	$	1,280
Leased		4,033		2,164
Total Device revenue		6,365		3,444

Stock-based Compensation

Fair Value of Financial Instruments

Inventory, Net


	March 31, 2021		December 31, 2020

Raw Materials	$	4,102	$	3,213
Work-in-process		390		1,455
Finished Goods		6,617		4,119
	$	11,109	$	8,787
Less: reserve		(152)		(152)
	$	10,957	$	8,635

Segment Information

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

Recent Accounting Pronouncements

XML 19 R8.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2021

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT

(2) PROPERTY AND EQUIPMENT

The components of property and equipment are as follows (in thousands):


	March 31, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,196	$	2,362
Assembly equipment		151		143
Vehicles		198		198
Leasehold improvements		1,013		559
Sales Rep demo units		313		361
Leased devices		1,086		809
	$	4,957	$	4,432
Less accumulated depreciation		(2,658)		(2,507)
	$	2,299	$	1,925

Total depreciation expense related to our property and equipment was $0.1 million for each of the three months ended March 31, 2021 and 2020.

XML 20 R9.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE

3 Months Ended

Mar. 31, 2021

EARNINGS PER SHARE

EARNINGS PER SHARE

(3) EARNINGS PER SHARE

The calculation of basic and diluted earnings per share for the three months ended March 31, 2021and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended March 31,
	2021		2020
Basic earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Basic weighted-average shares outstanding		34,837		32,913

Basic earnings per share	$	(0.02)	$	0.09

Diluted earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Weighted-average shares outstanding		34,837		32,913
Effect of dilutive securities - options and restricted stock		—		1,291
Diluted weighted-average shares outstanding		34,837		34,204

Diluted earnings per share	$	(0.02)	$	0.09

XML 21 R10.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS

3 Months Ended

Mar. 31, 2021

STOCK-BASED COMPENSATION PLANS

STOCK-BASED COMPENSATION PLANS

(4) STOCK-BASED COMPENSATION PLANS


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	296		296
Equity Compensation Plans not approved by Shareholders	38		25
2017 Stock Option Plan	490		274
Total	824	$	595

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:


	For the Three Months Ended March 31,
	2021		2020
Cost of Revenue	$	15	$	6
Sales and marketing expense		15		29
General, and administrative		78		462
Total stock based compensation expense	$	108	$	497

The Company received proceeds of $27,000 and $0.2 million related to option exercises during the three months ended March 31, 2021 and 2020, respectively.


	For the Three Months
	Ended March 31,
	2021		2020
Expected term (years)	—		6.79
Risk-free interest rate	—	%	1.59	%
Expected volatility	—	%	116.76	%
Expected dividend yield	—	%	—	%

A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Granted	—	$	—
Forfeited	(174)	$	7.65
Exercised	(8)	$	3.12
Outstanding at March 31, 2021	824	$	2.07	5.79	$	10,873

Exercisable at March 31, 2021	595	$	1.73	5.23	$	8,061

A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		65
Forfeited		(66)
Vested		(49)
Granted but not vested at March 31, 2021		218

XML 22 R11.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2021

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY

(5) STOCKHOLDERS’ EQUITY

Treasury Stock

Warrants

A summary of stock warrant activity for the three months ended March 31, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.52		192
Forfeited	—	$	—
Outstanding and Exercisable at March 31, 2021	90	$	2.64		3.52	$	1,137

XML 23 R12.htm IDEA: XBRL DOCUMENT

INCOME TAXES

3 Months Ended

Mar. 31, 2021

INCOME TAXES

INCOME TAXES

(6) INCOME TAXES

No taxes were paid during the three months ended March 31, 2021 and 2020.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

LEASES

3 Months Ended

Mar. 31, 2021

LEASES

LEASES

(7) LEASES

The Company has five operating leases; four pertaining to its corporate headquarters and one for its warehouse facility located in Englewood, CO. Details of each lease are as follows:

●

operating lease liability of $3.9 million and a corresponding right-of-use asset for $3.6 million. The remaining lease term was 2.3 years at March 31, 2021.

●

The Company has five finance leases for office equipment as follows:

●


	Operating lease liability		Financing lease liability
April 1, 2021 through December 31, 2021		1,768		110
2022		2,447		147
2023		1,514		147
2024		512		116
2025		528		73
2026		223		19
Total undiscounted future minimum lease payments		6,992		612
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(578)		(111)
Total lease liabilities	$	6,414	$	501

XML 25 R14.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS

3 Months Ended

Mar. 31, 2021

CONCENTRATIONS

CONCENTRATIONS

(8) CONCENTRATIONS

XML 26 R15.htm IDEA: XBRL DOCUMENT

LITIGATION

3 Months Ended

Mar. 31, 2021

LITIGATION

LITIGATION

(9) LITIGATION

The Company is currently not a party to any material pending legal proceedings.

XML 27 R16.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Policies)

3 Months Ended

Mar. 31, 2021

BASIS OF PRESENTATION

Principles of Consolidation

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of Zynex, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Reclassifications

Reclassifications

Use of Estimates

Use of Estimates

Leases

Leases

The Company determines if an arrangement is a lease at inception or modification of a contract.

●

The lease does not transfer ownership of the underlying asset to the lessee by the end of the lease term.

●

The lease does not grant the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.

●

There is no residual value guaranteed and the present value of the sum of the lease payments does not equal or exceed substantially all of the fair value of the underlying asset

●

The underlying asset is expected to have alternative uses to the lessor at the end of the lease term.

Accounts Receivable, Net

Accounts Receivable, Net

Revenue Recognition

Revenue Recognition

The following table provides a breakdown of net revenue related to devices accounted for as purchases subject to ASC 606 and leases subject to ASC 842 (in thousands):


	For the Three Months Ended March 31,
	2021		2020
Device revenue
Purchased	$	2,332	$	1,280
Leased		4,033		2,164
Total Device revenue		6,365		3,444

Stock-based Compensation

Stock-based Compensation

Fair Value of Financial Instruments

Fair Value of Financial Instruments

Inventory, Net

Inventory, Net


	March 31, 2021		December 31, 2020

Raw Materials	$	4,102	$	3,213
Work-in-process		390		1,455
Finished Goods		6,617		4,119
	$	11,109	$	8,787
Less: reserve		(152)		(152)
	$	10,957	$	8,635

Segment Information

Segment Information

We currently operate our business as one operating segment which includes two revenue types: Devices and Supplies.

Income Taxes

Income Taxes

Recent Accounting Pronouncements

Recent Accounting Pronouncements

XML 28 R17.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION (Tables)

3 Months Ended

Mar. 31, 2021

BASIS OF PRESENTATION

Disaggregation of Revenue


	For the Three Months Ended March 31,
	2021		2020
Device revenue
Purchased	$	2,332	$	1,280
Leased		4,033		2,164
Total Device revenue		6,365		3,444

Schedule of components of inventory


	March 31, 2021		December 31, 2020

Raw Materials	$	4,102	$	3,213
Work-in-process		390		1,455
Finished Goods		6,617		4,119
	$	11,109	$	8,787
Less: reserve		(152)		(152)
	$	10,957	$	8,635

XML 29 R18.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2021

PROPERTY AND EQUIPMENT

Schedule of components of property and equipment

The components of property and equipment are as follows (in thousands):


	March 31, 2021		December 31, 2020
Property and equipment
Office furniture and equipment	$	2,196	$	2,362
Assembly equipment		151		143
Vehicles		198		198
Leasehold improvements		1,013		559
Sales Rep demo units		313		361
Leased devices		1,086		809
	$	4,957	$	4,432
Less accumulated depreciation		(2,658)		(2,507)
	$	2,299	$	1,925

XML 30 R19.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2021

EARNINGS PER SHARE

Schedule of Calculation of Basic and Diluted earnings per share

The calculation of basic and diluted earnings per share for the three months ended March 31, 2021and 2020 are as follows (in thousands, except per share data):


	For the Three Months Ended March 31,
	2021		2020
Basic earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Basic weighted-average shares outstanding		34,837		32,913

Basic earnings per share	$	(0.02)	$	0.09

Diluted earnings per share
Net income available to common stockholders	$	(706)	$	2,937
Weighted-average shares outstanding		34,837		32,913
Effect of dilutive securities - options and restricted stock		—		1,291
Diluted weighted-average shares outstanding		34,837		34,204

Diluted earnings per share	$	(0.02)	$	0.09

XML 31 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS (Tables)

3 Months Ended

Mar. 31, 2021

STOCK-BASED COMPENSATION PLANS

Schedule of outstanding and exercisable number of options


	Outstanding	Exercisable
	Number of Options	Number of Options
	(in thousands)	(in thousands)
Plan Category
2005 Stock Option Plan	296		296
Equity Compensation Plans not approved by Shareholders	38		25
2017 Stock Option Plan	490		274
Total	824	$	595

Summary of fair value of stock options grants


	For the Three Months
	Ended March 31,
	2021		2020
Expected term (years)	—		6.79
Risk-free interest rate	—	%	1.59	%
Expected volatility	—	%	116.76	%
Expected dividend yield	—	%	—	%

Schedule of share based compensation expenses recorded in the consolidated statement of income

The following summarizes stock-based compensation expenses recorded in the consolidated statements of operations:


	For the Three Months Ended March 31,
	2021		2020
Cost of Revenue	$	15	$	6
Sales and marketing expense		15		29
General, and administrative		78		462
Total stock based compensation expense	$	108	$	497

Summary of stock option activity under the option plan

A summary of stock option activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


				Weighted-
		Weighted-		Average	Aggregate
	Number of	Average		Remaining	Intrinsic
	Shares	Exercise		Contractual	Value
	(in thousands)	Price		Term (Years)	(in thousands)
Outstanding at December 31, 2020	1,006	$	3.04	6.47	$	10,483
Granted	—	$	—
Forfeited	(174)	$	7.65
Exercised	(8)	$	3.12
Outstanding at March 31, 2021	824	$	2.07	5.79	$	10,873

Exercisable at March 31, 2021	595	$	1.73	5.23	$	8,061

Schedule of restricted stock award activity under all equity compensation plans

A summary of restricted stock award activity under all equity compensation plans for the three months ended March 31, 2021, is presented below:


		Number of
		Shares
		(in thousands)
Granted but not vested at December 31, 2020		268
Granted		65
Forfeited		(66)
Vested		(49)
Granted but not vested at March 31, 2021		218

XML 32 R21.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2021

STOCKHOLDERS' EQUITY

Schedule of stock warrant activity

A summary of stock warrant activity for the three months ended March 31, 2021 is presented below:


				Weighted
		Weighted		Average		Aggregate
	Number of	Average		Remaining		Intrinsic
	Warrants	Exercise		Contractual		Value
	(in thousands)	Price		Life (Years)		(in thousands)
Outstanding at December 31, 2020	100	$	2.63		3.76	$	1,084
Granted	—	$	—
Exercised	(10)	$	2.50		3.52		192
Forfeited	—	$	—
Outstanding and Exercisable at March 31, 2021	90	$	2.64		3.52	$	1,137

XML 33 R22.htm IDEA: XBRL DOCUMENT

LEASES (Tables)

3 Months Ended

Mar. 31, 2021

LEASES

Schedule of future minimum lease payments under the Company's financing leases and operating lease


	Operating lease liability		Financing lease liability
April 1, 2021 through December 31, 2021		1,768		110
2022		2,447		147
2023		1,514		147
2024		512		116
2025		528		73
2026		223		19
Total undiscounted future minimum lease payments		6,992		612
Less: Difference between undiscounted lease payments and discounted lease liabilities:		(578)		(111)
Total lease liabilities	$	6,414	$	501

XML 34 R23.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Breakdown of net revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Device revenue
Total Device revenue	$ 24,127	$ 15,228
Devices [Member]
Device revenue
Purchased	2,332	1,280
Leased	4,033	2,164
Total Device revenue	$ 6,365	$ 3,444

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

XML 35 R24.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Components of inventory
Raw Materials	$ 4,102	$ 3,213
Work-in-process	390	1,455
Finished Goods	6,617	4,119
Total	11,109	8,787
Less: reserve	(152)	(152)
Inventory, net	$ 10,957	$ 8,635

XML 36 R25.htm IDEA: XBRL DOCUMENT

BASIS OF PRESENTATION - Additional Information (Details)	3 Months Ended
	Mar. 31, 2021 segment
BASIS OF PRESENTATION
Number of operating segments	1

XML 37 R26.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment, Gross	$ 4,957	$ 4,432
Less accumulated depreciation	(2,658)	(2,507)
Property and Equipment, Net	2,299	1,925
Office furniture and equipment
Property, Plant and Equipment, Gross	2,196	2,362
Assembly equipment
Property, Plant and Equipment, Gross	151	143
Vehicles
Property, Plant and Equipment, Gross	198	198
Leasehold improvements
Property, Plant and Equipment, Gross	1,013	559
Sales Rep demo units
Property, Plant and Equipment, Gross	313	361
Leased devices
Property, Plant and Equipment, Gross	$ 1,086	$ 809

XML 38 R27.htm IDEA: XBRL DOCUMENT

PROPERTY AND EQUIPMENT - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment
Depreciation	$ 487	$ 252
Property and Equipment [Member]
Property, Plant and Equipment
Depreciation	100	100
Sales Rep demo units
Property, Plant and Equipment
Depreciation	100	0
Leased Devices [Member]
Property, Plant and Equipment
Depreciation	$ 200	$ 200

XML 39 R28.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Basic earnings per share
Net income available to common stockholders	$ (706)	$ 2,937
Basic weighted-average shares outstanding	34,837	32,913
Basic earnings per share	$ (0.02)	$ 0.09
Diluted earnings per share
Net income available to common stockholders	$ (706)	$ 2,937
Weighted-average shares outstanding	34,837	32,913
Effect of dilutive securities - options and restricted stock	0	1,291
Diluted weighted-average shares outstanding	34,837	34,204
Diluted earnings per share	$ (0.02)	$ 0.09

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 40 R29.htm IDEA: XBRL DOCUMENT

EARNINGS PER SHARE - Additional information (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1.1	0.3

XML 41 R30.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Outstanding and exercisable number of stock options (Details) shares in Thousands	Mar. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	824
Number of Shares, Exercisable	595
2005 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	296
Number of Shares, Exercisable	296
Equity Compensation Plans not approved by Shareholders
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	38
Number of Shares, Exercisable	25
2017 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award
Outstanding Number of Options (in shares)	490
Number of Shares, Exercisable	274

XML 42 R31.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - stock-based compensation expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total stock based compensation expense	$ 108	$ 497
Cost of Revenue
Total stock based compensation expense	15	6
Sales and marketing expense
Total stock based compensation expense	15	29
General and administrative
Total stock based compensation expense	$ 78	$ 462

XML 43 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Stock options granted (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair value of stock option grants
Expected term (years)	0 years	6 years 9 months 14 days
Risk-free interest rate	0.00%	1.59%
Expected volatility	0.00%	116.76%
Expected dividend yield	0.00%	0.00%

XML 44 R33.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Summary of stock option activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Summary of stock option activity under the option Plan
Outstanding and Exercisable at ending balance	824
Number of Shares, Exercisable	595
Employee Stock Option [Member]
Summary of stock option activity under the option Plan
Outstanding at beginning balance	1,006
Number of Shares, Granted	0
Number of Warrants, Exercised	(174)
Number of Shares, Forfeited	(8)
Outstanding and Exercisable at ending balance	824	1,006
Number of Shares, Exercisable	595
Weighted Average Exercise Price, Outstanding at beginning balance	$ 3.04
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	7.65
Weighted Average Exercise Price, Forfeited	3.12
Weighted Average Exercise Price, Outstanding at ending balance	2.07	$ 3.04
Weighted Average Exercise Price, Exercisable at ending balance	$ 1.73
Weighted Average Remaining Contractual Life, Outstanding	5 years 9 months 14 days	6 years 5 months 19 days
Weighted Average Remaining Contractual Life, Exercisable (Years)	5 years 2 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 10,873	$ 10,483
Aggregate Intrinsic Value, Exercisable	$ 8,061

XML 45 R34.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Summary of restricted stock award activity (Details) - Restricted Stock [Member] shares in Thousands	3 Months Ended
	Mar. 31, 2021 shares
Share-based Compensation Arrangement by Share-based Payment Award
Granted but not vested at beginning balance	268
Granted	65
Forfeited	66
Vested	(49)
Granted but not vested at ending balance	218

XML 46 R35.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION PLANS - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Stock options outstanding	824,000
Number of Shares, Exercisable	595,000
Proceeds from Stock Options Exercised	$ 27,000	$ 200
Unrecognized compensation expense related to stock options	$ 3,500
Weighted-average period of unrecognized compensation expense related to stock options	2 years 3 months 18 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Restricted stock were granted	65,000
2017 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized			5,000,000,000
Number of Shares, Granted	0	14,000
Stock options outstanding	490,000
Number of Shares, Exercisable	274,000
2017 Stock Option Plan \| Management [Member] \| Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Restricted stock were granted	65,000	165,000
2005 Stock Option Plan
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost
Stock options outstanding	296,000
Number of Shares, Exercisable	296,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Warrants (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Outstanding and Exercisable at ending balance	824
Warrant
Outstanding at beginning balance	100
Number of Warrants, Granted	0
Number of Warrants, Exercised	(10)
Number of Warrants, Forfeited	0
Outstanding and Exercisable at ending balance	90	100
Weighted Average Exercise Price, Outstanding at beginning balance	$ 2.63
Weighted Average Exercise Price, Granted	0
Weighted Average Exercise Price, Exercised	2.50
Weighted Average Exercise Price, Forfeited	0
Weighted Average Exercise Price, Outstanding at ending balance	$ 2.64	$ 2.63
Weighted Average Remaining Contractual Life (Years)	3 years 6 months 7 days	3 years 9 months 3 days
Weighted Average Remaining Contractual Life, Exercised (Years)	3 years 6 months 7 days
Aggregate Intrinsic Value	$ 1,137	$ 1,084
Aggregate Intrinsic Value, Exercised	$ 192

XML 48 R37.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 08, 2021
Subsidiary, Sale of Stock
Stock Repurchased During Period, Value	$ 75
Common Stock [Member]
Subsidiary, Sale of Stock
Stock Repurchase Program, Authorized Amount		$ 10,000
Stock Repurchased During Period, Shares	5,000
Treasury Stock Acquired, Average Cost Per Share	$ 14.79
Stock Repurchased During Period, Value	$ 100

XML 49 R38.htm IDEA: XBRL DOCUMENT

INCOME TAXES - Additional information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Taxes
Income Tax Credits and Adjustments	$ 400
Effective Income Tax Rate Reconciliation, Percent	35.00%
Discrete Items Income Tax Benefit	$ 100	$ 1,100
Income tax benefit	384	483
Income taxes paid	$ 0	$ 0
Estimated Rate One [Member]
Income Taxes
Effective Income Tax Rate Reconciliation, Percent	25.20%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 50 R39.htm IDEA: XBRL DOCUMENT

LEASES (Details) $ in Thousands	Mar. 31, 2021 USD ($)
Operating lease liabilities
April 1, 2021 through December 31, 2021	$ 1,768
2022	2,447
2023	1,514
2024	512
2025	528
2026	223
Total undiscounted future minimum lease payments	6,992
Less: Difference between undiscounted lease payments and discounted lease liabilities:	(578)
Total lease liabilities	6,414
Finance lease liabilities
April 1, 2021 through December 31, 2021	110
2022	147
2023	147
2024	116
2025	73
2026	19
Total undiscounted future minimum lease payments	612
Less: Difference between undiscounted lease payments and discounted lease liabilities:	(111)
Total lease liabilities	$ 501

XML 51 R40.htm IDEA: XBRL DOCUMENT

LEASES - Additional information (Details)					3 Months Ended			7 Months Ended	8 Months Ended	10 Months Ended	12 Months Ended			34 Months Ended
LEASES - Additional information (Details)	Nov. 01, 2021 $ / ft²	Apr. 09, 2021 USD ($) ft² $ / ft²	Nov. 01, 2020 $ / ft²	Oct. 20, 2019 $ / ft²	Mar. 31, 2021 USD ($) lease	Dec. 31, 2020 USD ($) $ / ft²	Mar. 31, 2020 USD ($)	Sep. 30, 2019 $ / ft²	Oct. 31, 2020 $ / ft²	Oct. 31, 2020 $ / ft²	Oct. 31, 2021 $ / ft²	Oct. 19, 2019 $ / ft²	Oct. 19, 2018 $ / ft²	Jan. 31, 2024 $ / ft²	Dec. 14, 2020 USD ($)	Nov. 25, 2020 USD ($)	Nov. 03, 2020 USD ($)	Sep. 17, 2020 USD ($) ft²	Mar. 03, 2020 USD ($)	Jan. 03, 2020 USD ($) ft²	Sep. 20, 2019 USD ($)	Jun. 01, 2019 USD ($)	Mar. 11, 2019 ft²	Oct. 20, 2017 USD ($) ft²
Lessee, Lease, Description
Number of operating leases \| lease					5
Number of Operating Leases Pertaining to Corporate Headquarters \| lease					4
Number of operating leases pertaining to warehouse facility. \| lease					1
Number of finance leases \| lease					5
Additional rent per square foot \| $ / ft²		0.50
Operating lease liabilities					$ 6,414,000
Operating lease asset					5,380,000	$ 5,993,000
Financing lease asset					457,000	$ 321,000
Finance Lease, Liability					501,000
Operating Lease, Cost					$ 600,000		$ 400,000
Lessee, Operating Lease, Discount Rate					4.00%
Operating Leases, One
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²																								41,715
Option to extend lease term																								2 years
Rent per square foot \| $ / ft²												19.75	7.50
Additional rent per square foot \| $ / ft²				1
Tenant Improvements																								$ 200,000
Operating lease liabilities																								3,900,000
Operating lease asset																								$ 3,600,000
Operating Lease, Weighted Average Remaining Lease Term					2 years 3 months 18 days
Operating Leases, Two
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²																							21,420
Option to extend lease term																							2 years
Rent per square foot \| $ / ft²								10.00		20.75
Additional rent per square foot \| $ / ft²			1
Operating lease liabilities																						$ 1,600,000
Operating lease asset																						$ 1,600,000
Operating Lease, Weighted Average Remaining Lease Term					2 years 3 months 18 days
Operating Leases, Three
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²																				22,546
Rent per square foot \| $ / ft²									13.00		21.75
Additional rent per square foot \| $ / ft²	1
Operating lease liabilities																				$ 1,400,000
Operating lease asset																				$ 1,400,000
Operating Lease, Weighted Average Remaining Lease Term					2 years 3 months 18 days
Operating Leases, Four
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²																		50,488
Option to extend lease term																		5 years
Rent per square foot \| $ / ft²						9.40
Additional rent per square foot \| $ / ft²						0.30
Tenant Improvements																		$ 400,000
Operating lease liabilities						$ 2,400,000
Operating lease asset						$ 2,100,000
Operating Lease, Weighted Average Remaining Lease Term					5 years 2 months 12 days
Operating Leases, Five
Lessee, Lease, Description
Land Subject to Ground Leases \| ft²		166,912
Rent per square foot \| $ / ft²														26.50
Additional rent per square foot \| $ / ft²		0.50
Operating lease liabilities		$ 13,400,000
Operating lease asset		$ 13,400,000
Finance Leases, Office Equipment One
Lessee, Lease, Description
Financing lease asset																					$ 200,000
Finance Lease, Liability																					$ 200,000
Lessee, Finance Lease, Term of Contract																					5 years
Finance Lease, Weighted Average Remaining Lease Term					3 years 7 months 6 days
Finance Leases, Office Equipment Two
Lessee, Lease, Description
Financing lease asset																			$ 100,000
Finance Lease, Liability																			$ 100,000
Lessee, Finance Lease, Term of Contract																			4 years
Finance Lease, Weighted Average Remaining Lease Term					3 years
Finance Leases, Office Equipment Three
Lessee, Lease, Description
Financing lease asset																$ 100,000
Finance Lease, Liability																$ 100,000
Lessee, Finance Lease, Term of Contract																5 years
Finance Lease, Weighted Average Remaining Lease Term					4 years 8 months 12 days
Finance Leases, Office Equipment Four
Lessee, Lease, Description
Financing lease asset															$ 200,000
Finance Lease, Liability															$ 200,000
Lessee, Finance Lease, Term of Contract															5 years 3 months 18 days
Finance Lease, Weighted Average Remaining Lease Term					5 years 3 months 18 days
Finance Leases, Office Equipment Five
Lessee, Lease, Description
Financing lease asset																	$ 8,000
Finance Lease, Liability																	$ 8,000
Lessee, Finance Lease, Term of Contract																	3 years
Finance Lease, Weighted Average Remaining Lease Term					2 years 9 months 18 days
Minimum
Lessee, Lease, Description
Lessee, Finance Lease, Discount Rate					8.30%
Maximum
Lessee, Lease, Description
Lessee, Finance Lease, Discount Rate					20.70%
Cost of Revenue
Lessee, Lease, Description
Operating Lease, Cost					$ 200,000
General and administrative
Lessee, Lease, Description
Operating Lease, Cost					$ 400,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

CONCENTRATIONS (Details) - item	3 Months Ended		12 Months Ended
CONCENTRATIONS (Details) - item	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Supplier Concentration Risk [Member] \| Cost of Goods, Total [Member]
Concentration Risk
Concentration Risk, Percentage	32.00%	40.00%
Accounts Receivable [Member]
Concentration Risk
Concentration Risk, Percentage	37.00%		26.00%
Number of third-party payers	2		1

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ȧ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�QC&X?=[<*)1-==X 0VU\Z;FSO,&[X4K+ M#G#9T>$REB>*\SL' .S0W6>* VAU< #J9LI7I_H8"YND#F#3:85-+%.^%E+: M)@!\#@Z^[3/EJT)976$Y:R\ M'N;L(7, KH[.&E.=.==.S:8=F[0 3J<5.+',N79JMNV("1=0Z.(HW#YSKA7* M5OMS4!>PZK9:UVZ=2HINMKD'8+>KPVXLE?"3!Q<8[?+=IY(+]'5UEIWJ5.H7 M.JNSV&V>P\!5MQ57L43J%U*:%@"+KN)E@JW3J*]05J][7$"JVVI5NWW6:+UW M0+P66;/R?B[.[4MI,)R%F!80V-W#]M\#MGI;L57Y J5"UNUR] 5*#RCJX7B[ M]'\JQM(#FGE[.-WT &&>WNNHK<=2\6J4T77PP00*>C@%\S=Y\USOBV<1S3!P M>T V;P_[; ^HY>F>.BK>1O:J^VQL^>$!D3P<%>AS.TTRRVA MA<\#6'CN'L9OY2U]W:0RB5-;5L6R8OQ/5 M(<&%%&W<#SNFZ&2>Y$ S,VY]& E9*2'.8 V6[H>,[^X$%V:12#[C1H, ;6(+\5LRYZKF6DI ,AP.!XIP6!+4@>"UHGQ&$M2!\+>B>$;1K0=OL3&7%[,,4 M2QP-.-LAKJ,533?,9AJULD]R?>Q+R=4L43H93>YGDYO9PV+T<'L_6Z*/4Y"8 M4/$)72(B(1NX4BVB0]VX!HXK8' &&*([ELM4H)L\@>2$?MJL]X,&@*O<68O! MWN(X:"3>8=Y"H7^! B_P3R0T>;O<.^6G63Z%^)S\A9O0'EAH>.TSO&59%)0 M1Q.6QY!+CLW[LR#B$?V\@VP%_!?ZHV:%1&R-OC"6B OTP"2F=KXAC;9-HVW2 M",\]-T>K-T [%MII]'8,O4!SX'I,74&GGL5F7ABT/._#J2-OUK6]8]T+0UUK MJ-L(&L4Q*W,IT )B(%N\HO"60^A9?._]#N'*0J_>^1":>6'OS"%,FW5!]S^' MT+>&^HV@6:GW6[\,,B4\N2PPE\^HP,_ Q2D[%:UC:+IJ;J-@X&X/$S^.\&U$ ME:)[<"-GP#>FL@EDGH;JYK*CMGB.3,UX-3[VKR=5#?R'J2JRNI(PEHA MO59/Y<.K*E=U)"O,O;]B4E41TTS5AP%P':#FUXS)?4 P #A( T !X;"]S='EL97,N>&ULW5AM:]LP$/XK M1AVCA5$G<>/&:Q+8 H7!-@KMAWTK2BP[ EGR9*5+^NNGLVSGI;K2]3#R'=QW,RAZPU-PJ70=VT5P?^?-\@.@G8% +D0G<$"< M83HNJ3%,RVL[J1?7QB=0T(SO-J55F&NZZ0^&9.M0WVR0N=(ITUV8/FE-T[%@ M&(.2/RCS>66W(^LY=!F[T2SCZWJ^SCH!&'L?9Z=E M*3:?!,]EP=SF7QQP.J:M7[!4FC_::- J"VM@F@0/3!N^V+7\TK2\8VO3MM,Z MPS4/CE#SW\USSB335.R*MKW_EK/\:L71Y;^27/]7.13LU=@<C)*WJ3&L#D:=\[?O=.WLP;PEC,AW^%]26R#!O,5%X;+9K;D:_QV?$[L=A MF+:1%QFA/B/4QWGYD%G]P>+X?1)[^7>:)%$4QUA&9S.O@AF6MSB&KY\-TP8> M6!R(]&>YQJN-=\CS?8#5]+D.P7:*=R*V4SS7@/CS!AY)XJ\V%@<\L"I@O0/Q M_7&@I_P^4015Q;1A3S".) F&0"_Z>S2.D>S$\/'7!WM*HBA)_ A@?@51A"'P M-.((I@ T8$@4U>?@P7D4MN=4N/T%:/H;4$L#!!0 ( />(G5*7BKL

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

80N2J8--*/9"SP51?>]KLCT_W B3&9/ZZ=Q'7DF]TQF/'9_9S*O7E"\1_]ZCWW*P=Q^ET,B5ZEX M7[=A-M#?X/Q:,+6!:_K^K9/?;+/-+;B)*'L*-MN"S;9@L^T+R:K/F%[<;&L/ MTT K]@L=GNE&GN1PO6TG1!:A+-&__D03P;F5H'H6;+8%FVUG<4H?W&Q+MW-) M/1:Q5+ZZ&'5,HR;F 3=$KBKZZP_U^&HQ+?!5P69;L-GVA@&^M-E&;4VP(LD6 M4V/I^*38;0T,GA8VI(ZC!6>SC0X'FVU!N!!LM@6;;2?V5/N;;=211&9J]LPG MA6PF^,XRS3<8,2D7K3IR36BW+?Y ,M1;FVW_L="C_ARXL!OQ(Y]>P=J";&\6 MK?&&I&>565K(Y^;ZT_#Y;%5T;0%,N!HTX/_")\"_L(8X,"PLE-@"CK"%1-2" M#TZJ\#M7^GUAG!Y)S&S#QOA0=3GGJH*BUN&B T'<0HJH2 -L%E.).,8F9*FHF4F_"&@'X M7P, 8@H?/3() '\H.^4H(DP]$$BN#X1B$C/X2,03)!-]H.K+WWBF;D1AL#IO MO;#C-Z$'5L69"7Y[?_B?BLXRCQQ*HZFX"F$5T[R!.&4\T;9T[P/L_IQ/]DI] M_MJ?Z':?^2$9W\:1_/GR_ MFUV(.Y)^/"^[\,T+@(H^DA>HY%] !!]L]+A)Y;]IGM4;M)6;EM?Y3>LMIKTC M(GR->,^I;CN[*/K@L]S&MVM=@;D$YG)"M&.I*1^O%>RK]!"X=1-\QHS%UHK:/%FRBSE[/%$T-L+WP;0U:+%"!'56T,PAC-5' M%N,;\2FG)EJZ86<0V/P7T.P^X@% @2=3@P2=F3!D<3(RID-[G;Q%#[#/L7*L MMVJP%KMZWZYQJ6ZFGUY5(Y51KBY$D0-X%1'X_H.-"U(5W+#/^$8!Q,%;7Q$; M\UMZDZVMO.)0ICEQ41V+19YD^*:^8OG$+%MTF>"90QKXO^\VHFCCR"H(*&XJ MY0Y\Q+5]A&,6KSB(8J(X;.KM6'72W'2F(&THI)QQB1XCB0\ZB#L+.=ZJ;USC M+,D-NY\3QR:WWY9UD>K'UQQ1?,/%ELE&7R,['"=7QUI]V>>&-^B(WBY^#!>E MO"QE\Z$)Z*0+R5!F1)M+UJ%CHJDWBQ_7:L5R.UN\Y95^_V;".5J;3-33]+SI M"/4FH?D4M34Q$J%KF\T,?07GWP+JFOC7F7L.!4M=UEHMOL2'FE95U=:A8LG> MAY./?D!%M[V(P%@H$CBNL5MMP\IIMG1+5/W?IW33JNA6%\ A2_I0@]*4_;1A M6_5D'/6LB(8AR$;#,$HU2>!!3.WU:Y$5&EGFTDGV('ID?L1NH[R3>2$*S>':D25 MN&ID(@LEJIR/)9;/[-J_?,T,$,(+&()H"V]M^)FG><>OG<45"<-\W-M7A+=" M@EF>7J2/;LVBY>-=F8_3O M%W9F7_X5?CATHKHS3[]Q)ZNJ:.#Y-UXTYX9=O_XT6]54,5AT+=TP'7^Z0*Z6@'\,#7&*/+D!9C;\-71HA#U#'YQKH8WOAX_P/A:. MU1R#0LY2UU!(MA=.PH^GNN8/)1LQ,9JT-Q6>G [ZQ6E)KC:EZ>?7:7SKQE8& M-4-IW'F]LKFV!F84EZ^O)(9 Q]BF^N:!+ 2SH:)/H M-8YO?_E:O.;)3[[>5LQG%>K_M_?N3:DK3=_P_T_5_1U2Z]K[?M9^2E@Y<%SK M>G<50D $ 3F(^@\5D@$B(8$<0/ST[_1,$L)!!14$S55UK:T8)C,]W3V_/DRW M'N\Z77%X@;\G*O?F:=!8LDV*E?S;.6I#Y]?5*Z"$F?BGXD5N.ACTAY)^ M/[^L=JH/X]OK'__&S["V6^B.$)".VC M2!>SR# B]3 Y?DO:3)I;+NV3Z:A?T^6W[V$3"/!AHT+\;R;P,ZQK;8?AED]@ M'Y[T/#(G;8;V+KJE,$HR^-2]C%-L:_\LO*\OE'^DA0_E*.Y&MVROU=1;P]8XJ5;/2#387WS*I2;8H-IEEE6I5, M*U=LBCDF6ZTTJN5B+@._Y(N53"5;S)291A-_<"56FHT#3_\ME\1?5+[+4KI) M^"1R*G0X7DHG$UVY(Z<$H1/K<7PG'5?X#I)E.9U@E40W+OR@/"9YKMK\9>3" ML;K2K1BI2(_=UMCI/A2O\=F97'WRO,JU+POGB?0PHE_=*#>)I&@,KSM\)[;Z MI,RB#LI52G4Q<9NN5!)J;]2,P)-K8W9[H_-Z(JMC6-71.CV1;^2.K33OQ M/GYR;:+B;7)N9\8W:-@6IX.8W;UICRHPYMI$^;%U;];OYC$V.\K?1^SKR_C$ M@2?7)SIVXK9QQ??X(7]S/1:>N,E$O(7,A[4G<]G[RUR,K_7%D7G=M^=/V6D] M"T^N3;1UAZ_3)W#D^NOO[**C_%R:]H7&Q/K@1 MV_(#]$U=9]%NJ]EG8SF;35S>Q+5(];9\,8$GU\;,#*IQYZ[=K REZTHF55#* M-PE$REBO#6H,JX/(@+VK86[N-O/M?H6];\W@T74%4>82,PQ-,\-1[_Y!GM6L M2B8_\XICDV=7O*@O^PQ=7^#^_4@OGDUMR21)@?YYLV^/JSQ BJ.A:F^S[]6; M3]6LPS2M=0]LPLX(D8N[=*TUZG7,9*? /$R6B<_]X4"(6 B_+?G *I*!?_$A38M0O5T5H#J4T9*M]6'[RU MH,KG4/ PYL6.Y21.K$C-%V+";VO.'#7!#F/]O%=(0ZD[$!/)A@8?DFR8MV*H MV'XMB=UK"'D%TT/6^ Q9.CZCXJ@)=A@;Y%,4ZO31276FWS=17[)1"'F^RUGV12'/[KR_6LS]:V][ M"&'"8^W[(!B_PV"XV5\>P_@MVT(,$V*8;X9A%O< OO:&A^CE7Z]K=;C57Q^^ M!/HBA]O]Y0$,*8$1@I=3 B_'W#.)PI23:IFTL2O2Z7/!\QO]\5CEI/:[!G5Y MPAW>$:*$:*+EIKD!7L]32JR,U7J66.FD MM?-,VIR9]M#)E:?=IE,^3Q9!Z<2A4'M""+7.9VF=3[_4OG]<Q^;9^7C>GM_OC[\L%ZC%"->;C6:2.!SUX[6Z[HA% M?9ZA?35)3QW^SU;6RKX:K7W/@Q@?+XWX@BV\SNR\.?;R8=?\^<; MSQ]'A"\44_<.MHVVW]=QDGV'D/G:HIF?7]Q59?1XJ.RM5\E 9D&"(_7[HK3YBUT(J-A\S@?ALV_ M;=A\_QKD\\W_ \7./T;/%'7V3KVZSUZUU&:M%(G/]9M[]AVVT#OC9S?( E6C M*^+C&,GXQZ8!'P4BZGXMJU=#Z[-.K9V^[?(/+:?95=%#UA92<>AS2$+K:?Y+ M!=;SAME#:AA:/[9;DF'H_5"A=U<"''-A^6Q0"MUK>UB]:Y\[K,3E.6E\F>N, M^]>==!AZWU/H_;-E[S"A^<]>9>A@.4CH?H..V=&[8J)RKMA,C$VVS945H5"; M7%_EH5%R&+_?2_S^LP7S@/']SUYJ&/\_.A&@!O]G,\9!9(#:_9^]U# MX#U7 M[76%"3@>X>K]U5);]J_M*#Q4ZL"RC A81A3# 7H?@Y <[CK^E_2?;7,;W[C3 M6K-<*8):V5+V_*$Q<"XZEYD.QX(-G [C>Y^<:O#IXOG)N0B?OO[/MZ4/JZ!. MXSI_6RW.XE:AK;"3\N#F^J+J1&[&1&O1^_POW9,+]=;^\Q(^76R/(7'ATXD0 M9C;LLR! IC#/=EDU6QA*]Z-&OXA:7(\E.BA,;?AT[+3NZ3@R)72 D@&?OOXP M+^+S2PK(>DMXU#+M')NXGS<;W=RX/!P0+45K"G!"\K74AU\V.&#^7=-F'RTD MJSHD\*#_G._,X\?;UQ''\P;.4'5'HNL[E9GO>YYOG]F;P<)-1W&>ILV')Y8? M5\:Y3O%B8MSV5R6DJ,O&"#6EQYQJR9IA.29JXA><:X8\=%F[VXD\V*6.-AH5 MAY/.>,SQW6HZ'\=#(2P$8SR8;6*)^"@BN@HRHJ&>_9OSJZ6J.B:1_3O";2@C M"_3ZTS\!QL/-V+&)(1J,:J% M%2O^:(27HS".1;W!>%MMK$QMQ!@]QL;C23J69XW!QR/":FM*1\:+1F>,I#PX MD#I&AEJIM,0;( M"68XQB!J%S_CYM)'F3P>%^9@#TR$F!$FP\!B$-X#9<5)O?+VQK51+5&.7[02 MXN6PE![;B;IP_>-?-KINL3.8"37\0Y3)K+K^">WA[)3T.;"+[)@F?B?>4I=) M7)9YED6 AZ0Q9L-'PE+XBUONQ!AKHHXCR3'-G(PG8CM[4;R:CX4[O;K;5EBF MO4 B#1GIF",-@D">YH]J1W1Y7:GC?ZHZJL6;UHBK)).^0F+%AXS^I>!:@.Z8&? M. M0V^*&]ZC. A4R!2VT+&8'EZQ85K1@RG656WJJ5E$5*D)1P$H)LFF"\#4PVM! ML!G+FIJSM[CH:)K )G,6#;DVU8>^WS;YA)UJ&E]G4%NHO[]+WR=Y=LH?K@-J^P MI.52N;'OT)\7?I\JK]Z8D69W/*1!0S4US$O*IC3X4;KEB2K'R@#L7D?TT=Z[.Y0@V5P]% MI?+@2N;TZ>2>=<9R(69/+MN"@8\9[@4J$9X;4^G2YDN:): 0]:!.";#D:3+A M&BR#6Q.ZA1:T5?LZ'FLCD9O<=3RT,)_.[NH7HV+_96!VPJSX+EKE MDD8IG[^L2<,1F[B3"O.'GI C8KNN>'U:;:U_E_5F@(?WYA$XM@T4UMW_>!-G M6&@MI#^[@\BJ2>I:DC_9L%C3N&B(:@:Q_&U%B_?%:F-L9_:^\MW%_,-7WE>; MN8M;N1@9JBH:]7*797O^@'5GQ=C@]%ME70HAB:$ZQB]XV^D?]5UPAW0='H<7 MJXPPH+:JO3*R+(1>Q4)>]. E#^G!*XN9QH%]=QYV&FQO$:$]A.BF: M]WKFOJ5J@Z;&8ZZ0<^^\ ]P$X&F3O3]K:&88RAF3K4:9',)3TBS?>T0HRN 1&*P5 M>H:F&3/K-U%))&#H![5I&!IK,4T:6^BW]\.?#]!77N@J\(EMC,FO9 X139H; MCOV[ISXBQ4L.8%DO-NY!A^7L>?>Q%/W;2HC^Q4FO3G(E;$\4.Y[?"XD+J;58 M_/_^)YU(IO^LSF,E8!\\9I?/BW=1F?X*P^)Y8G[6EIK[NA\%POQPMJX<&:21 M(.$G+,H28T$& N&;/H:0Q V+9;8JVX;?4P],'Y[EDLQ,M0=,ME%@&G,+W 7T MSQCW1@D#KSCP71Y;,,78'<[J, ME]-PN@_8:&T:!9+(\L+QFG8JH^YLD*VTYH.QDQ+S\OG-(]98,>XLR:V;TL>Y MP8P%AQ'6GPC9U,\$D4LO6N!SN^GH%EA-AM,?,)>.CAB!<#DOG%$VQVMRPXPD M&FF#FYXPNV903011"\LW5%9,W..:\T;>B^,S?6'3]U33 MLA<+6V5A&K&#,"O ,Y_M#8/$T8Y3.%]Q3@;S\4$!C\RKF3P6LY=L9)ZYJG2% MR^2@^2PX7(@8],=B.UP:?DN]5^!BTW8K.VE-.L-$K%ZKWF0=H[Y[ 4&"+;&4 MV1A(-LA6Y?%.;53#8FF0>.HWA\(PT5(FA7ZL_/C0R_SX-[FYO-\Q[C/6H0.5 MQ#-E$Y$@)E:BQSG5@[!D:HDET^]E2=LN3TM/J-/%C'FI9]2Q79CV]\F2V>Q% M^Q$;?"D655,S3DARCP\S"/FDH\F3 08!=RD^( U=>5ZW$CN6V%3DKS:D(T@] M#"0\CH:!NO-GP,!QK?L@#)YV&=S[[9T,/BYDG]*\P);$ BOFJKW^3=Z1^[NB M8,+@&7]_MF3U5+?;,<9FA:W&"FV-DV).-P&L?BILO@(&EF.MX"_4,4*8(SN8 MTS<;(.!Q1K5IAHID88)UL1$G4[<'Q< TVX[X*4R*%SV(#.("0Q-!P?N"L T) MWS9T"S,76)LV23A422(/ >3'23U,"-TG# CY<4X3J$D5E:9*U&%/]L!57AC? MK^P[I%)IEL$873R,EV,YEN9D,['5/C9,(B0VUH&0Z0X*L>NH&KGYOW"D(AJ5 MM>C@6%M&-/Q:3 V%N@_(L* I3+7KV.@D/ (?'3 _O$=@IPA[$^F2;A='D*2& MGD\,O9DG6D6#YY#(3X3BJ&P4A'1M!C'U3949CW%?_4B_;;;!O!G?Z'WUDL@O19W^ M^U_\C[]3^#TFW& :K/AP!2!^P$6[CVM(,O%&>L$N/N;=S/*#75SB(!]-0@D*,A&A?C?3.!GXB!?W>&1]!@)[.-RW)5^S?N,7 OS/S0L IU^ MD[Q\=8I@]*5Q?0<_ST430&#\J[NP&(=-@STQT$IL5%BPRW\E9F""%OY/LYK= MM,>'=KR3P L6;M#[H')\_I$^,EC\K$1M$2N_OZN(MV=,L9*-?G (^SVSJE2; M8H-I5IE6)=/*%9MBCLE6*XUJN9C+P"_Y8B53R18S9:;1Q!]%_Q'&"C\R5GA20<)5>+,P+;#^.DZ, M]\VP^_)[RM[^; 3P Z&>+A6%^TRK79B-TC$U+PSMZQ__"M'TJ0%X0-@29)Q M_JU!J]$1H!(Q>A''!^( W(]S)=^:3>M FVJO9:$,;--&9F6;L6QI6DSEV.S- M>4PK-5JM8HHP:^+$F#5ZI--KDEBA6T+%5?#$\"2WMK:,8J\7;W@CPTWXB_[T MO#'.LHUFIS%II9N#X?7F(/:F*C.;(]CNXLAO*X%L1VO?75W&D8! M(Z0K)#_-34%=SUP[8Z2N,45GD,%&&)-&^#C"G5SZA?R=XR+#?I+4A ['O2,Z MUYP9KO;N"O+3I)J^++)JJ:O6S]6+NO5TH!RUOF!JG;2B]ME$B1\WIA?MAWH) M(P6>.XOQIY(>$ M97G SF_*=?,]TV]/>ML[P^TCYZVB/8CI8>$J$;?DG#6)J6'.VR%SWA@+ M39%.E^=>:7-%(1,\ ^"#QNO)<$& >USTV&=FQD+VFD8GW1'>DY>Q$,0;U&_< M#,NI"[%Z5[V*C&:U8OX^L\?$HV$M6[R;W=:<5LEBIS%+JJ:ZYY"-P4;94]'V M83+]]#Y2 M/ !@L:- P M4-AWU17@*6DVO'B\ZFI-?YQC*R!-.<'*CNL].3]T:D97J!92][G!/EU;]6Q) MD4<)+39LU!^3I<%UK5'/9#"4%D[)V1JXH?D]_:P;':UOA=P!?KR_>!@FRL4X M+ZJMX7W"*(Y3;6FV3WY\K-7&]L78:4F%MI2UE41<&X%*YT[(U;JJ(HGKU?.4 M,L^X70/%GYNA]W07KN>"WM,/8'JV45%RJL&E6NUN9W35[-S78['K@_A/(Q?M M2OK6N.F)DZ&F/VJ1[2G-J;5S75=YIB<71QV4K<3I[N+M&%?.X %-Q0 M?OPX-S?TJKZ!XRXL,QV9B+GS8:.?[*;K%]7K27*/?E6SUY$%3FFUQ>J=Y%@Y MK2;/ST._:NA7#?VJ1^!7959$S3=X9+O )YPS&]==4Z_5B MI^7D&@^-HEB,C,\Q$(BS9[%4ZE2PP(LU02F7'^?,%YG=;L@B'FCGL-FW2Y]( M1(]T14V?XJHN:XZ"K&?3SQ=9[X:.WI* OG\1W$<&NF'%$EI1F[;9R6 H3N[* MC3N4.3Y0!$7W"=XX$6A$\Q6CS#DI_PO'&14N#):.4U+V7+@OX"3FWQ>T",C) M=:8_FXSLUK7HM/HWUTTU9=C3?2:(QP6]Z.@"/QCRA4Y%+[78QS[T,4A'8Z<2 MLEAR[$+@+Q#!V%B#,G3WG@+_[NKNK?0[=T5#2SP.^5[+:C7C);9X23J^"2?) MR;O6GL3'//SUC24HWU;N4-NAVF%8Z7"SO_.0=LX^*AUJ]T]2HV:+J6'DZH&3 M!W5)N&4SFSLM'N>^;E'I\)@=H)[0!G2"/<"H;#THQ!@RZ2P.M9E-327U$R5] M84X@:D5L,I>LI7@217XC:0AB#JTEU9XJ \TV%8DD!1YM@]Q15/4I_LS (Y/N MS5C/D/8\\%:WO'0.R=0_0B_,?&!XZ[M58?JX4UW-LIH\+AMP'E_+):9 M^$EIWE(O*R7VLEDUDC%(N-G0V?DX]]@OPW04H;7 W@[2C2>]>3D9LXU8J2VG M,WHC%MOL0/J0R%IZ>MVJ%6^TVV&U&K?&(S/3&UP?7QF#.)23/@GWT0E$UKYP M(MD1O9IR+@WX/,=6;Y_FM\F'RE"8[YP+ M^+8XG'*3XG.:59.':I&U'VRAS\;;<)DZD3A+3V-Q= M]H4;$"041M(,&0.IP8C#W#'\\C$+E:U+#I^K$'8CXN6J+ M6C<4PL$6IHD'6>KN'K:!>]$S' OF ;OP+?9NT9^.[OK:];TLB 4E?ID]=ZXC MUZ-]YK[KC88YNK!+5RUU;A2TAU:N>RMF,!1/G$X7N"^6O'Z4T]JK)*5]2?JP M,[1:*A0O>VFMT4*5?MUJUG)55'Z;(.T:8!$D)8%FG=G=4'IHW=?+@W3::5T? MGH1J\[Z>UH2TU1I=7MW.ZXFID9T=)L;4+";TR\$D8PP3?$G6U&:U-\^2KCX; MEA4BN N6=(FZ((.37=X/_JV;E\K"/+)O#8HNYGU791 7'.0BN? M=5\7:7>_]0T#?C:P;Z1YN\N6(M>7_+#>GCVJ1UBUQ7R^]DKA%KZ35 MV/R67$O6V;DK7Z:O1;;<;O$W,V'&1@K]CO)*Z3]R#"Y6'Y< M&>4LR,*REVY"BL.,#U25,_Q=,:71SE>MUJLW\ M,'N-Y:(N%'E]UJ<);6OLAPTQ,A[=7HMF(U*K%9\SZIAX9R3X7-.,F?6;M/D) M<^J_N>OOI5HE"[:A&F,IJ9YGW;K-Q+]7,G1,/>9*U0W-EIB:B480]'99G+KU ML,2-\8>_L)FE>]X,TC(*O]+RG($D2 WQ99NX6!;N%<9]N%Q-F9"B+\_:=U"QVAW?F]1MR<8-O@WE4>][$ MN&""8>=QWBY/)Q$1%2[O8TF4Z=R/CC"0PIQ2(6C"W;2EII?W/79,>4""=$O< MY_K)("5\N47F4N:(@6AJ&61LR?92JMAV;]&5,]("U 2=HLW/_&2UE1;&J-># M%[A3\4>#]#3XZU32W,YL2W<+%L:"#ZVC3-T5)CRK+AY*4A7JX=-(;HG$$)5- M'(-^X?>M!'3GG)/E(^[#[E/7"O?CQ.5MH\%.M//+0?Q&CB?G_>/3U>%]ZN.V M>PY[B+S1" J^].6$(*Y1L80"FBK#D18IU*[FB8IV>YJ-E<.;U6]BO2?AW%#/ M(U)U&.E$4OJ#?J^4P 6Z4RI(\%4O)H)DD\DZGS0+,W8^N[6F/)_5TY?'U_J* M='H[">RR>R+(KY6VK:?7A#L9-N$.FW"_[%@*FW"_I]UUV(3[*S?AYG=JPBU\ M1A/NT(-X7#!C1P^BBT6"%3FV"KO5T7H)>R\*QT]ON].X MX[0%L63'=&MV/K[O&YL+''V [_#JR>2DQ];3Y3 [>6PD'^ZKO1O]^NAX+1;Z M#D/?X5'Y#@>5[E->%7HQ<7[1/G\LJ@(RXD>8*1'Z#H_;=WC0,V3OKD-UW+Y) M)?D!RT[X(E<>%_AI/4DJ!)S:]:S0=?@VUG-BB=3-G:J7Q*HC/E:NYT)G8&UN MA/L!KD/99BU'[-1&8@/E)I;6GR:GTC&Z#MD3@2[A';+0#-RK&>B7U^;CAS % M"R;&/% 7Q6+@SP,#8%!/DBD$Q, V"P24%.-U$W$'PQ :&\<_[%@/5+\U;ZJ\ M:$8>9D,4J8L=MB&GYNF]&8>M=+]9:D=N.N*\%KFO5_C4?;)P?-HU3"P)C$)=/L/.[]*Q6?W)OJYR>\OFB-Q? M5=G)Z/%VF+C-S;F^-5&G3\<'&F+1Y(D AMU-LFVN;FQGMOGI!"\93BOFR8KQ M\A%VT8?F [P43WPI%: Q'W4-[?\2,XU+K01L7S38#C?['8TQOQ(<%]O1&,,* M0,-&E^;87MVM UMBKYI@?(>+?=31&:B2E!4O)BVM-1V+B;M\IM+K=Z5:_SW* M]'GS2ZD)H[@RB&>&!:%2K&DU>B5]F;PP M^YL3LG<"IH=$I %R-F)//?6RE#D7I>2 C?"3VTHROS= .LD-;H4GJ]X;1F[J M3TX,/8V;L\Q+:G03UAJ'ON_0]_U1ON^E+*B,9JNVHR"F[%;4IYCZ45/ M[EEMRQ@_K6#D-L!VJ=Y58CR^R&?*?;8ZJ)['FWQQ=C7&T"QUAC?O5#S! M1^H!#FQRTAY52_S]D]D:/3[&NEHAV9EE]I:3,XU=M%I]7C2'<^5B7BU-8I.( M>7P.8#Z:.I%#=C\.X-._\I<*K_R%5_Z>W\;7?F3R 'Y>"+Y@_(8_493[ECL*)?CFM>W8OLQ,IG? MG]M7%W=]*(BV^F1]4DL^7.13HU:B:,Q9X:*?UA,9_&1\]5DO,.GR'77TR)TA/0O*ASHF1QJ5BGM^J%?FQCZ'0VI-6*1.3U*[4 M9D>%.9?L:8/I%9?IQ-:?C%C]A_,[3>RP$U9BSYM*HC1H93KQ]2>50AM%AA,Q M+O+#A'ACJK8R?#4O7JNI-=]/J3(A^YL-I5 MG1U*:66<&$24]/BJ#TT&UQX=)5MYIZ3*M=;(&57+E_5+IZMGX-&U_8QT+B(W M/>EIWBKDZJE8?Z:95_?D46]#=[])*NQ!ER^[VD!ZN.0?:[41E<4H!@DN065T5<\"-0X>&%<$XU-9+F=O/PBKYZ+@V2[ MX@_IL\$YSPQ' X>C[)C,YFYDX%4A[R(%K$=DUHOZ[_Y4Q]*<-A*#6"Y#'-?X MG5C!/2$%*L*K^"]3M.Q]D39$#/V=>6&Q8 \%^Z@1O\^6)O/8,5''D>289D[& M$[&=O2A>S: MK:G>K=95TC_K$;.8@00M!X(283$]TQCMG?R6:7?JDMY'Q'2%WZZP^8C5DY>. MIB4[[7[[FATFS,B@HH^="3][Y_8$[=77-P=5C/APW&BGV49]/IE?ILOGPO#Z MQ[^I19 HL#F8:3^!9-)C@&2S7C4R**=:PU:C85G%\Y+*Z>G9(4F6FH@QZ?XI MI;(E0Q645&=2SL6@;QP+J56K-#O#BE+%UNL,ZS)0MD3RJ=JDS5*?<;_2T-OS MCI,W5G#=XH+;E61CE6[/"5!OXO>=:X8\_.$=@4[D>MHJ#::/8D%6[E+M:>$A MJ6&>19A68SRV;3IH/T?A6^#E#I%*^E:PV5Q[#>"G3(T4SP] #$3)L0WO VH= MDD^6C$AV$>=SGUEW'=BF-S'WA9P;K7PNAXQZ(=Q1$M@B3?T=I- >LZ\^SD'P M8I*5 MO\=WZMNLE#X$:[L_+CJJ=$^&"5XAQ:'8(A7EXR?-%M3^V=#1?9D9-NB^]7B6 M+"/4ZZVF!'Z&4EPR1))1WB.2JF/%9_^.T(^6J$1[*KH!5K_3HG=-@G*/P)W1 M'^"939*R*TV.'PN]_>CX.%H<"TA*>2&_H A],G$.8R@$- PQY8/!5F$I-+^M M=VSG4DE;NW,C[_7G^FZ@FNL;ISDO"FW@ _ZP.Y(JXWK&A!]>3"73S[>_W%DRD=J0UW3J.F27>.CWTRIOI\[QZ9E#F&U? M5L]L=#/OJE^:Z'HN"=7,4RM;ZJ)S-6M48\4^UB\)K%^X35F3QVVZO@&EX;WA M3\%$6<<4&^R/TW0:?24'Z)?5-UOAFIR#*G@^3=*+]@JN7E@;M$[V_#9ACJ^L M-CN9GE\V>K.\J#0@2P>C&OXL%EN/^(4"^KE'Y6=);(@0]H40MI/49.>)ORK. M2F-QTF&%!5E_"W@Y68P2"VVG$T0< M(; X7F !U3 WJ!N-M7LY\^KN85BR6U7YQA3XZ<6L$P=H$>D*729O6&=8S=]WIZ)RC2%'@D ._BLFAWQ)"0]]&=]$ MY+=!+\^(NF:WBN5:3)SCJ5^DK^^N:TU4ZF-1Q^ EN7ZM]&OZ,A*G:3-]@IE! M]-8G)I$?!1$H0/EL*GQ9;;83@%&GFTRR>C+3RM1:=F& M@DC@FTE_:]=,TX#"-W@U;A$-I# ]QX9*%R-:]V2E[DYHY)VDLCQBFR]$44> MHC8H3:/=*TGRG<"W(D/S*1\7!T:NUN^D #TESM+I[6).H6XX>MUP:@ZB(Z;7 M:2N+UQ#6IA3>F).];F?-^3!1<9KEWET!SQ8*2&)DE7@Q+/UE/$>@8G\S.;77 M0R94,V2ZR)XAI"^#JI7JA5#=<>VO@8)YOT_3%OW@^/UG2_KG6Y1'#HY Q_T\ M+27W(B)J!416?)3QHQE2B72#YN.ODI/&P\")L_-T\2J>[)H32\YTTB0ZEER/ MCOT32O012'3H-/H&(KX1Q^P@VE*^ZPP3O'G;BB1N$D-#CQG.)8@V2>59[_O] MS_=S&*T!EB]F^QV3U;-!<0I80RB& X52/P4+_75PG] GK/C+VGG/@)\-FO!F M/% XJ23.Q.K,B]S"-ZDHO!-FP;(M6 ME/_HIHMO+"O_QH;@RV='%B]K8Q]PZ2;;L&9\8BY6FX+44H6$I51('_#U3'B_ M#S@XQ?9-'39(';93XIY*L?* .Q>1_31WKL[EB*%G]DV=NM7O-&OI[E5+FMK7 MB>G@YI+-98 ZZ^>I3QV_IRQ<0*"=9RWH4HN4E6Y[A(ZPNC,&^L B&1HO:?,H MD]]VA+-#,ZG70[*HR\8(X=%MT@>D#"VE\;=(8PGO&:!JM=? 1+7/TH*4F:=H#>[NAGS;1+'@,S5%(8V\R M*KS- CH=1++>L:4%I$,/GXRN9!1(.[!LDW0+$Q_'2+>\WJ"MA\'D]J;:P).J MEJZ;[9JD]^S];S/7+,U%H](9EM1$[K+^^%1^R%V_(JMKV]&G*Z0=FI?6R""Z M2-+1"*03TY@X?T@S=Y(=*Z;*GBA'AJ7FELI6)HRZ9-OP.RGWM+35DP@<2EJS- M/:*:6<5^&C6:'1%EZX/AU:->F^E8SPOKI_G?7K\[?+*-#9T$=+TF:$C#>,LT MH'.?-)Y#?S_%D6VW>9D],Q@+FY%J#UO!6%M.,;\8IL7\5%"/M)B3+,8".LW) M44_[HD%7W+__V1Z]L?[4/H_?5E#V,?+;Y>-U9%AZ%!5V4C!F]Q?%^(VVC/SW MRV^ZFBPE;QIQ4>3'J9E:2NJ16@'S6VQ3BSW,;T%>>X&7H@?1@%>2CE=&3OPN MPE2>(N@WB1D61(#V>L7G_T =8YM7M0>4J?%F8"2*(4_FRR8,",TX8="II&JD 1G%0 II7XLAD8]_W+=[>'T_ M],8DSJPV45\^1P:2@@DC(W4*L]VM.:**P5JG%K]6YV,[46I-8K&6\%@Y']B% MS$<=(VOBF)%)[,VJ^W/VY%"_*27OA$M'E&YCCOG0NF>OT9(<%BOY)4F,6$@& M:9P9IF(AW1/%I_FC^ANCN2[4)6X.5%.I22;)7\)\Y\L@&Q#!B5 H%NX:XZ$X M,B/RHWF=F;:3V S'HK4.[6T8,3*&(2&-!WB9I/,M7%CBUEG5K4UJ:FSYS-\ F_HT>B=P#JR&F*ZD@6<3VTFVWQ/# M/R"/0)+( ,+)V0?C)B]&E&8J^RBU+F[RLX.($G?1D\7:/9\> MJM,'\<%YLAO--MX[?&)M(4J?*4F?M!/[%:7L9;M=N[4K33:12&O*%7][)Y;P M=O#KWM>M1' M(ZW/U:\['2>I]D_0J$__LV=#OEQL%@O$BC^<$4] - !"Z"^._[M\*E"8!ZY+ MABHJ_!1DNO1I9:#$9X[!(P9?(6I6GA2HP74IDW4L8QBOJ$CN?W7%8"GA F) M'4H&Q=@:!)GT?,<,"M 5L/=:/_,N7@9 X:Z/>NFH^+>]8=M ,W!&M1B"I'5; MHRA<6A"<;@2>L(H1.,;?"O5U]N$WTY 1@@_V9/*L:B+Z%S]%#_*BMDT'.$Z= MZ4\#VT[8P)K#'-V^REO/"80[XK9"?GE2B]FSVU-.(IJT(RDI3F%[7$?HI;A. M#"6$3C.GQLD2O@*B&X?'H W@T\N /;$E*2?__G_P1)NI[>X>KQ *U=GN#) MP=1'D:Z)I&%$ZF%R_):TF32W7-HGTU'!2_'X[:=R"$19LU$A_C<3^!G6M;;# MT/,[L(_+YR#]VG);;^]#PR+&_6_J>)@B&'UI7,(NMC'^S7-1:#*.U:;'[#$N MFHSOB8%6SBQAP2Y8( 8FH)K_-*O937O\UE?27V$@K 4P*M66^CFY'P48&X@+ M>IR<&?B, TA$;P>[_",%>>@Y<5S>MTW;015 L2E>\5>92J8@7HF59B-7;&1; MC09&"YE*#G]6!;#1YG%RD *N>2?!K-8(8.7R'AK M9*IY)E_$J\X6,V4F6ZWDBDWOF;K8:)6;\ C%:M6:N.^XR$8U\X8>8(?=L!__ M9B6'>/4P3*L8MBHCIHXQA4G01=XP9_C'2-DPAO"['[BV#D;&SZ,:-O4M9N)@ M^(59> Z.5\.TB3DEJ;JU"/.ZKB^)XDU"+XW2ZXR"3VGI82K1F)@8TF&DH=-H MB5MFP##[DHZ--GRBS# 270!K#S=CR#I%FC$F$!B,UBE).#^#E\R0IL%_ 0RK M&$_*) )M(G74!?A-OF)C;*G@QUVX+HU52&"W/#@)+^SY365IN 1C]08L8V5Q M&.13FQW@N:I/#0W\WOB]F$K@@L> ?4AAO(,-9A.(!C.EQ)()> ]X["'#H]=# M>,KX%U56QP3(F\AR--NW)UPBX3'/B'%.F%2;NV3V'@9C12$7$-W8P,"P2,C> MA,M.)+0/4'IU.8$M(KZ7[ASO!@3XNV@@:3W/,> B=6R_#! >EJ[231L@#[B) M@["]2._CXYY!9&&0-T#S3S GX:F RP(^M,Y_9//9H8U'Q(@%T7IC.:&R3,5?^'F0Y](@G!F/X?\3D4PS9AH >S 7O M 6$U8#W'Q%P,'$ M6W8L#&F1:9VM3![^&)S? $D:%K+%:_ ?IZH"SFQXS=*,SA@-ZP80&3P59*MD M822:T\=@S@9>HV*#I0EO+A62#I??0, M=18.PD7Z$W&Y&^YZ$!Y\'@R*K:X6A@'K'K;")1/DPE'NH*$A++D:62IE+W<$ MRK&$Z5!_[C(ZT13PH8%_4%03Q)8^B.DFN[Z#A0;*5F^*N0B7AEG F)XN.POH M-RI'"K)D4^UB>D%L2Z6>!95^*Z/K#B94G:IA/!0^G$88"D=*?I+/''._&P1> M="2AN]SBC:M&&$^_:/_'627T-44;0 MW"00*;FY=?H#UO!D-,K8H#7H9DF85T"/+^5';9H;907=L!'AZBV>#V9J!?2R M"QHM&OM_@6?@?9;3M=#$H=Z6GJJ1$P<>Q>/3J.A FH):0%/5<"P-G&!(=Y_T MU]I LF.24Y@,*CY266:(G]2R,%T.PWNG CC=_,9O@""7IA&\V($Y*D*N=OSX M]WZNH\:GA-\TE10)"X Y=BVE?S 36B25 )]7BHM'"202,?A!,XP1 MSC"O86M*4HPHP[21&_$GP7U\'KA)M/,%AK10GYYI(Z20TP>#2@S\+9?I/32S MDKT#S#T&;!)PPGH'3)3)D$/GY>BB+YR&#GC/Q418"%5%A0EB[4/(P5S1>7ED M<2'+_57QS 4M^/B9#0Q-FT>,&2@O;_W+A+,'IN'T!^ZR@@YMK&#<; =AZ'#2$]/'T!SWI%R95&.W2<%NNB >,I&8K@8H#\-G9T02F;P7TCUQ MYTXC4%[FTA1O&<8OL*"WX42%ID\3'4F.6#CB58!R,TDE."XK0L*%B_-=]/B' MIIS@PP,?\7C=9"F2/(",%U#>>)93I#M4A8/NCC)% MY7=QI4I<=DE-#T!6?N M;Q6$?\VI4E_'NZ/*:R2OY'8C.2RQ-I#PF?;4\]\15H<,J*B@LBL PQS-*5X(_>!/U MF?H20T$0&CRA1/20BNQ3,0Y#$ISBK(]DX+HFK_XF-1;OGJ&Q>/\A]X MW2OX1JS83>HRB*?^7AX[0L;VLB0WO6%)JY-\*8EDBT!8&73V7VPTZ<_;/6B? MF?K:W.GI()F>>0'CJN3*$!F9CZ:W''DY!SK*9"5KP/0T8V8QCNL#6]R76;@1 MW3N9\:CPEO=PT;9!(8/G5Y16TS;I9L>Y:-Q[ >2D8N5"]@,6*?Q-G3]_Q8.K ME3:CRV,\]TXLZ,JS87PSC&\>17SST$B1\@V,Y< #2Y""+#C[2 M-' NJ"3+BE2>PC9WC3H3O+GXI[45N :\-.G%=5[(F)(TW^_]W+VC0*(:'D=3 MB;O;7#SPU?%_P]O:;6GKTA-8P"%9< ON@. #%EWB60;'4O\ERE,N\F-$WAOA M/8[9@YB(^T7%W="N9(,G^^N;9*X"HF%A-P\1DA ]E]R21*J6ZZ &?PNR,7:" M,Y:1E ?'HAFY!,WN3T1%]P'O8O5.HZ^,Z657@RZB*P#. _2/_^T;P"E="?/, MLT$&DO5H66[H M1JSDT&(94$FX%FP0DD9@.=V1:L/?NI1 1#VXI%V*R](;:G2C?!U!_6H0G'<# M_2[IW7AYE&E@XP(6W0C*>>AJR24* )NE+P4[3ET79P',@?QJ[K_WJ>@C"!K(L6>2"'^%1XG&F M@3FX[X=WC$;FH'8!R1/W'\$HU2&'\ 1C"^]*YJ:P>C#WQ8L_+SB$E($FR@7. M!62" @Q((WG#DGI1K;%CNVAFBDB>^2:Y]',UO/G!\Q86?YL0+*!Y):8'"0[! M"5%]09_T?-;2TEU3G5P-HC)"Z+!(@H<'(4CCO3H*T1F()N*W$+I.);#E="P=7@CHX5(@D"8,DG+G8$I93PQO6?3G)LB'12Q*R#$HOE@6B MJ+"Q3R@QQ@1U"(47%SPW9&/0&ZUKFTHFT#/],"IY9Y \1J]G(5A3']*F;"]7 M9YEC%LJ!9O$0XM%#9Y%=I5"V,_ZFV!Y8U.M2,/>:PQ).,.+ M:$A4!9(\"3(.YNXQ+1NS<FZ5$+QR1R< "6(?2UNW\DW80+SMZOXNRQZ) M1MGLT0,K]K%&%UQ<1+0Q_R&, M-_J@6GR@O0%D?W46>=$\SU'Z?A\+/;=F]ZXP(+"*G^^VFN,595:_OY Y(+G+"AB]ODKCF8#&5@-B$G"+V2\)&#$6;-M4NX[MJ5M[(U;BY!O[W\?(=KDXM@H1CU?RYX%./ Y-\39FDT&6=&KKUI(7&)9XN(< ME3@N&4V]XY3C-GQ[&YFS7O3[! 'P\P>7"^J]/[IB3"7-?:\7?....^'MU"(T M7'@M+@P;A6&C8PD;+:H9NQ4YO\-EJ)>OD+E)E)XOF^2Z<7\\0 JG CDKP^P7 MFOWR'+U6@W!S+VJR'#+9])@%,99% BNC25WP>8(#:XI,R!P^8Z"6V-ASI2EP M"4E6W41%;T8>/M@^WV:!")("Q3CQ@('_O*FP1=+**HJ15R:Y!&)K;VENY]"6J>_SC%M1=P=)P(6RK MFLS$BQ=,P>ZBOA3,0C($TU)68A-!IKQAPM8JJN>EQ<7I/]JSE!)[][DXWRN619!JC'P$T? MBTBH9>@ZT@*#V:8T18&:B,M3E27,[A@.N?$+S2M00Y[%-N3SJWN3$N9BKC^5 M$X*V(LVHBR8^0@U;+TQYDTJF57XPBUB!4%O 0^/?2UO:KK4-6*P1M!$)"[ZL MR%^<9U!UQY,[JVXA^8KJWD%S;R38XKL0G( H#"9>@'/.2%T@E00>:(1E$>98 M;)7WED 2)YWHM_:*%0*%W9=+['\CM;H-3BUL40%_)PW\;EWKP@GOKN4FU3LV MC1ZR:!R;Z2$0E2#6I8L9&5AXGESP^_HRWZ2*8W$/#\?7\/#N3L!UI][K_0DV M:I> ?P^NLNO6@BQ=/&)/M?VO![">KW.#I2F\H2RJ:Z B!=2/6.R1-Q"!EO00 M@(71E#+W:M7RM4974]&E4Y_BHLJ >\]?>@9U;H*=>&)^UCC5S"\=&5N0U,M5 MIZ!?V!WTQ[<'"_I_^>/CV?.FQ"'__B7-F]AFM+C]W#Y;'%"- =N M-H7EZ3+WNHH-1**Q%ZC3 E+K9ICI)+T42>2B,:U6X(I EX;[-M_G[T+JA)>> MYMW875166;R6(4J%9BSY=1TEB'_(Q!/I"5_/P4JEIT+!6%(X8O-MS>?? #=9 MA/@.\A]EH#RJ";EG4"EY*>P4T+1N8@N\Q]7'I'R'91OR$)O+1%FC1S#B"0RD M-XY6[TX%/B!7>MR,MB?ODJFGZ;VDG,#B=C_RGKMRM7V+K:4F#>16L1Z12$=UN :GQ#TZX)S$29"]4\LX .&5+[U2MK1DPS%\F$H-@S%AJ'80X5B M5W4CI)02+?/B)>;MD0N]C1RX[;Q^_9J\SDT8)JG$&U])4=B'N%<_>GT;C<1@ M@G;PY:H.A=(-<^[:HUS0_%X)# 7;A+AM$:Q ?NTSPRY%D."@(:K$\RJ,-9+= M[9G8!/2.53?%R*\,Z?J1,0M:JI\N.X=;,.">ACY(6(>MA:K\,G13U73VVAKJ M!88%2EB;-I081&XV^_:0FW(PN^!@]ZK_JZ^CA>Z)W66ML$EP?WH]B'GV'%-7 MO=*;!$JX]4>A1C_LU *,:HC$!.OUAQMU[IU>' W:\,=_1D?TO;"]SD\L"BP M^G:E%33YME!:&U])E=8N>?-$67WT6M85%$B_@Y4%M7G'&'X.B#.,OF'N\OBK MZ]NA]^NF:;A-%;P."<\$JRQZYL/J]8#?A3K_2ZH5U #*BD?;# CA*CT MS9:+?9RY;Z:5/X@70:%* RZ^J&;P*I[7RY%F$#SB'_ 9,_7V*,H4HB;A!W8N"EK@7@3NY__Y-.)--_ M5N>Q_-#2)BT;.I^!M:LOR:.'ES84R &E'#2L%TP%B_\%V_2+[&O(8B&+K2EA MG[& C8)EEOX 'X:L%++2\ZR$\;/#"D5>U)0!1)9O4L9949D31ZA$8$ZL$&GI=VS!R\QX@ M6T[=S/C9*0V#Z*AOV#1=(^A/]I]LH+%-(^XI+_*5]R&T#A7YW4F2>#365_XW M5QW1P7Q1;\4*$S_#8H+M?&SS6!O7"IRZ9"&15&A&PM(-071:,P,T)!>+)M-@ MZM#1OG%6U-O#-]EZL5G,9LI,)INMMBK-8J7 U*KE8K8H-DA$1VPTBU>9YH=' M5'M'FI4JWYNCM?=!!Y;F&AP M'9:&S8D)NCQ L%Q^H)P]*0B!=0'U&;C1&5,AL(%:AXNB*VX4"!QPBT('M*O& MHO0^])[%OY%Z*V2"&=+;3SK@+< CV-L:O95-"A![+D>W3O&B0;R?5Y!;YH), M@ L6%6RR2QQ07W! U>, OPPV_CLIBL-O7Q1',V0_Y>YC>FR<[=X:@;P$=4V: M\!\_._3UT2-@G+UHY6H^SYQGRIE*5F0:%Z+89#+U>J;B]HP[;'7F(Z#Q:LE> MW5BM41/Q+"=K XNR32!4P/]O8CN!"!!/%J294"YESFCJ4/ 1) B"0](7O]6 M9M'4B^80,6OZV5?P9U[[GX!'=?GO?N%&B!3X*> ;SX2S19C^;),[CHSA?>ZW M*EI4V?%;S'I]@@!2@8,?;DZ% .D-]=&+C1)%0BTLC?5FIHA!TF>BH<^C;W$I M&Y=+0_%GW8 4[JQA8H$BD3E 2.0H]5N5N8$[OWT%N.O].H@DI]PSI[BEMB-M MP]04YH*V^:J2UGI/;MLC#/>QV8)G#"EQ?F20IMM"DO)(E:-,>Z!J:,D(4532 MI0C,&!"-@ K!DS:=L6L(&2O]1':JHDW]\-Z3;">62G*=5+J;[O!LG)7DF-1CT]W3;-/, M"V$25)@$%29!O=ZF6;AN9?!9W\PTBSU::LVS""Z@<_J M,\BA]QH,FZCO8,DP3&R+@-D!:,5O#8Q?Z&*II4Z.?CP_$/<'4@27>8PG?JHG M"7Q,P>>\G(YU8C$^V4EUDUWX/*7(\71"CO=<:5^HB%BV6FG6J^4&EI):O9H5 M@K\TC;>3&;R)&$P#0H=3S30TZG"K M00J3 D;_][B^!_[U17?*LT"I>+CM&,P=)3&C@8IZD+8E.^2&%\UV-)F?6;%* MFP;2)P*JT'\B7_WGC)@V7@EGFHOD7Q?3W>+$ANOQ=W='#N[.V-\=YB=I"MGS M&O'6'?"X(_$9T+%U?: D>9<^_F'CD77)(0QQ6L'Y.3]B//5ZDE MBJG@JGQZ\L!$J'+8=!-E"_*1ZM (S'%ZT5!:>.C@#JU7Z$:#MILTZF(&V[+3 M9#]()MS\/;?T]:)KLGL6NXEMY#!V9^EF1I,FPO1[^%GPBL/Q1VMP!_9O:=," MER7/O-X&\*-%.L>!H^+,C02YG@_7<>\7K?:,<[>R^N)$-1VO$@8LP=_V+;SS M/QMB]I\SMT*'Y!;O#E("LO-DV1DY-&>8VOBCD:.KU MS<](02< V1]D)F)%T:KMF!@(9D*=5*XF[#@DZ-"!_N!BY3;O81J3^)<%],V M$D.N[V.1UJFC&1XBI9Z6^M@#H^%!SX(M?_VKI!YNI.UT-[WE#/SL(U)"E1G@ M7207"19RZON:@+-E2?>%D+0'WBB)<"63-)SUEXI',Y&R6$+W@0HUS2+U2MJ? M^0_WB?K_: HQ(P? ->IIR'7&]7Q7G$V*[5-]X=ZE\ULJ^5W9\7,!&JO6DFZ1 MR/6&!T?IT[_JJQN^N"@JNH) (U":URJ&-JUX-O#F]I.A M+3^V%-A#AYAW]F&>CCLX=NRD#-W!H3OXL]W!M4R]62Q6FQ=BO5C)5^M7I$UV MAT\F^43J0_T\'^7.DE@><2DVWNDF>\E.3$[&.ZE>5^ZP*5Z1>GPLGN)B^W)0 M+2N=5_U3/_X%\C+%8I0A%&8")#[Z1N0+7R!7%@N9,G&)B;EBI=#H)+AX>J_L ML3>?'Q=ER&J8P'*.?BOV^H^/QCIK'&:4OS M^BG_PS3(Y:&Z?[?JN [@?4Q#7;:NB?$$><&J#)QB60XRF9I'#=#Z(BTCMH@< M_/>7>E02L\-%5OI6,(I=@QBL.9E:@9ZCA5C@$3:*#XH$FTBGXRO&.3NV5RSS M)9=,E(W]3:^K>E-R7\71!2YNAZYO0T; M3<3"C3B"C4A&N52X$4>P$:%$',E&L-&T$&[$$6Q$/)I*AAMQ!!L1JJ9CV8AT M-!Z>UD>Q$Z%(',U&I,.-.(*-X.-1+A'NQ,?M!*D M5R>ZUV^C<.M.K7#JO>J MA=^]Y-3JBH/W+X+_?L!B7K/$/V0QKZ0&_)3^^;K;(AL:,-[_]X/_\<:%):*? MOT/=+[Q#>T+%!]D7^0OOR_LEA\>B\R(Z.,@>*8$]"H_7S^?&XUORW@_AK1+T MPGT_]))?<_I^P26_YE[]@DO^AHR]?W 4:K3CW/A7'&.?M._>B[+X2UU3Q0-? M0,,*6!F\1-*MR$9H=Q":O>K#^L)$"_%PJ$6.TRG5-&Q)"['BL"W-8T MI3*Y+)\?%]P^Y9W](G'C#%32>U3AQC7=UQQ+^+X4H;B3- M<>7WIZK3'^R!X5B2KEC_+(/(((= 54?ZTTB:A_CC>_'^>_"'6\#!O23!C1\9 MTM.2\8J^?/)QYBF^[[[%'P1.CGNWQYZ93#3;=]_R=V&7X][HFM/55%ES#ZJ, MKAO0W>O5]% M%@ZVY,.D[!_5DK_A+A]/)M/!EGP\F4PA8Y^R%^H(U_P-M_D@B4A'M>0#Y1'M M8\T;D.9ZHPM91JC7^_.Y$#2]2H$KTAXF!<71KY8ZQ6S:T5T7]6D"O;;,YP/L M'[6FO>/*]++91*J>!M['"$O=898X.SCIL8E(L13\#!,_PZ;>"Q)\,OM] &WV M4;38.S)=X_V_]KFT??X9Z[DOHN;TCV,/JN?VC MTSWP??HLS2UQ5CC'3O =(W!7-H?P#/3B4;NBOJJ&_8*NWD:TJZ)_=%*-7(0HXZV,@:4Q=&V!!B[?L9U8Q=#1$7)N-Q%CV:34 M[233"'5BR12'.3<1ZR02*,&F$G$N%I?7.#=V5:R(C4Q>;-[EBHULN=IHU3'+ M"LDTESC)]F"Q* -+8NB:F,"BOB6K_LH<(:>B5)H74EVV(RA"K!.34MU.NL=U M.QSJH9C,<[T8EUSCU/A:W\YT3$C%DZ?(I/'/[)$9*LXC:P/N(8^$("@2E^H@ M(:Y@J8BQG;3,]SH(\[F23"<%+"@NLY]:=^KXX?0N?7 'BS?L3MT/NU,?0W=J M.!D2XNU%\;S8;'02\3C+?^SA%EC9@V/9:F]^J/,N$5VO$NNM]+"PC#[(;Z\? MEGO9K>F$'OG?GP]JFOC"D/\)%N_4)*7S)_*9(M_4K% M$K%D_!=6P!S'QA+Q-(__DQ*2Z5_VB.F;R(TP@Q]QB@DYI@9FZJV")QVYZ1G?1?9,X1TYGZNH\&=QC_K,OHGNF;H?P.5=4"1#[7;D:_S MB[.Z@&?V_TZ9@4\<#&YYZC[-']4(:')6$+A']"APRK&<;B"3\, ++PRL:DMF5=&1%JH\:FC,9V89/>9;EO^5Y]7X9"*4X-.EV M.C3X\- XQ4.#/^Y#(Z_JDBZKDA8>&N&A\=6E^+L=&GQH:9SBH<&?GJ5!G'!; M'"A5(#Q3PC/EF(3\^YTIH2%RDF=*:(B$ MAT9X:!R'%'^S0X-CN6BQT@C/C<_CN-OS>IDIZI:-E2QBBP[,2IKL:-3P+JOZL NIEZ$>#+DRU(/[UH/ES'FH!X]%#Y:E+M)"#1CR M8Z@!#ZX^ ML<9=HUBH9)JDQ' REN;C7BGMCR%W<*6+LG7/EZ=9S.8#97=#E;W@&2@DCO0H M#^;L07:WB2:.:I)*$):?\8UDQ\1[BZ!J@SR0]#[R,OBXM! [<[_85RVHA&0S M \EB%$>;,[+D0"5Y>Z!:4$P?:CC@UW018V$ZT9H-*GY-%PTDK0=%&& @4F30 M?0 *YB-'QU\BXTF./3"@OH1RF!KR;SN7EVL'GGB)P 4:C[.?6"MMO4 :J/7U M]6U?">[4%_9Z:^-M5WA0*_!XYGA_5Q%OSYAB)?NR-^UX9OP!#J(OL)BCWJ(W M,OXGMF)?7\,OZQ>3DW05:^'<>MB9ZY_A)2^,/F^+-FJIBV8TS7AI+3(P M,C$P,S,Q>&5X,S%D,2YH=&WM6O]3VSH2_U=T=-XKS,1QOD /',I,"W0>,Z\M MUTOGYNXWV9)C#8KE)\D)N;_^=B4Y<1(H<(6^'D=G2F)96JUV][.?E:+COT31 M>5G0,N.,_#;^^#MA*JNGO+0DTYQ::)T+6Y"QJBI:DH]<:R$E>:\%FW!"CKK] M7K?7/3R,HI-C$'4:QJ@R(?OQX"@>] 9]TCM,]H^2X9!G>Z[WV>?3 M\3\OS_VLEU_?_WYQ2G:B./['\#2.S\9G_L5^M]+W1YSJ:"V:+I-_K_3*J*&.BG$22YS8Y ".MFK28%,LVY9>6:"ZI%3..LEM2 M,\FI3E)EB]'F!#>-K)IQN2IME-.ID(OD]5A,N2&?^)Q\45-:ON[X%O@T7(O\ M]17W\2EIZN33+G;CFID@Q>GE\7(A66#/O= M_G&<@IVJ)] J@Q#E>D,M['ZK9C-A0"\I["(I!&.\A!&_OCH<](:CXQA[_TA- MOV7 T_,OXXL/%Z?OQA>?/SVR!6^WUP\USYH:%QTR+F"8(7^G)9M0JEF'9%Q; MD2^(+:A-GKD!^MU?7_7?]$87I* S3C2?"3Z'+&H+8<@?-=40/W(![972%G(K M^:#TE/1[T=^(RLF_%B6_[I"+,NN.GKFA!L%0[ZEQ)$.F"W)5JKGDP$8=;Z]@ M):9@FE(!C8$\*DI"RP6I2ZMK#GH!23F. _-1,H4G+:@D.^W MU:'D&3>&Z@5VF=(K#O.V9!IH8Z ,3"D1U3@'=LB$!F*%;D"U!C1A7)-Y(;*" MF!K_K,;/N>9!""Y@*@PP -*&IV+-3<4SIR#*K4 UQ6"9,QC&2+IHF^&Y!\3P MKH#@)!W8@! 1BL0(O M8 !A8$$]M(R0X!RS,34$(7-4W<$>M80.$!8*?.>F,TZ?C)J"Y%+-31,SFD^$ ML5#\6$*QT>L-6G9:KC>-,EO:/G?O[P?O WVT;863]_\Z,L'!@4D0/RK/!3PZ M*UX0JKGS%]A?I)*C70F'($FE, 5VQVY3R!V8/_"9"9-)96H8AUE%*^D=5VD% MY3,T&[(+?F(<'.^=<7X-]68)E?([ .R76D*/_I!&_8-=ON>&]@^8?_*/ DN% MT@<,RB>(ZE8<>;^B+O>>*%^;*(>)<)V;T04]D'L>DVG7RM_!?O>@*8L$Y+[2 M)E%H6[F4-/_#FXU "R6XDX<3_-# 6U_-07>PM1K?=M-J_)N-U4 P59(N$E%* M<&*42I5=K4G$67VQ/QAV#[<%9$HJG;SJN7^C[UJP^SKB!MQ"0CM'N1DL'R3:CM;G_$&2]E$/DAYD\CZI:@P!(AQ@2 MF&2A%R^='*P?5^FYG>+]I@F@%(AT!8=.2/_X4D"J!EV,DH*YK:VI4R.8H%K@ M H2G>T@6\IQXZ0[&$\9X^9W%^@^MRAFGX3JO>FG2W$WI^P[@U< /M,,,0C-:JD MR,S4 ):Q<$:0PO:P 0Q 6% ?5U@RW30MI@^'+0<;C_RUKJW"VQ4 UV%!5:TK M@*UQ)5Z6*^$1"NE#5,#!+QA]P>C],9IM M8/1\1F7M. <#F.].6Z[\KOWK21M-G0NRW!O"=!GA,)?4/6"JGNCBFTRGP_8[<#' Z*P MB7)O;D37 _@."T^59;7&\&Y5>3=(G2ICH1U/BD&6R4!0./8CN[<,R0&GP$0; MO8/B&:#'G6WAL5=9+_7:\UH5U"Q+8N0PAVO.'+D[>P3B71 IKK@,!UT;_3O? M;:+'QO+/>$1Q\'U'%.X\F#41VUFE122CLX;T ,.'Y%IZ498)#](?R9WDB,.?T"NL97^B[ MBL9M4=SO ,WY[(,P%3;O_G3QADQ*&0PT?)E(;\5?V-C $ "1PA_%7%%EH*(R M]13<"U9SBPD$=N-)]I,63/W#S=AS+3=$WO#-"XI^>A1M'A*\@XHHUY#V.Q#3 MW#$5H,+])A7@T_$%A2AG2LXX5A4EG82?UG0@-SZMI%IP>#LOE&,/'UQ+M*"TD&1QV"-VP>^^)"B%@'VN^V!%YE<6'V=@?C#*_< MN$.=("6%S,9U!-$O:65XTGQI*X9Z%#YX\0H,!@+HMX[A-JC]]9H5X-QM&9Q8 M-[,&:7V_*LN6:\)*#"KJ (Q46:NF0V0<)\C7%:EW9:\C%<\5>] MQDC-MMIVXM;;8:G3M ]T8XBX8M5]=$W?&3YH$?+L=G@#:L8FW M[L X\#R:\YY :9^)5FK>[8>5ONM.0$?_R1[X/[#^PY+9$ZA\6E !I4?9(9<: MBFSDF XY+03/R?DUSVI,"N1S:P-\Z4_2@>2WWO],7/\_%R:Q8^ FB?XL5FSE M]6))U"G-KB9:U26+U@ODUK78]1>!F[!$=Y5X>&[R2?LZ;FAIW\;=O.=;03T; M>1:C.12B"9TIP8)##P^[@_UE%O-M/<=1_OZPNY!\\A]02P,$% @ ]XB= M4@!281^G" 12X !@ !Z>7AI+3(P,C$P,S,Q>&5X,S%D,BYH=&WM6FUO MVS@2_BN\%+=- ,OR2])-Y6R -$EQ.6Q?MG!QN/M&B53$"R5J2D$*-+:H(3F>(570*N.,_&WZX7?"5-:4O+(DTYQ: M:)T+6Y"IJFM:D0]<:R$E>:<%N^2$O.T/!_U!__ PBHZ/8*C3T$=5"=F/1V_C MT6 T)(/#9/]M,GY#/G\@NU^GIWM.^NS3Z?2?G\_]K)^_OOO]XI3L1''\C_%I M')]-S_R+_?Y@2*::5D98H2HJX_C\XP[9*:RMDSB>S^?]^;BO]&4\_1(7MI3[ ML53*\#ZS;.?X"%O@+Z?L^*CDEI*LH-IP^]O.U^G[Z! DK+"2'Q_%[:>7315; M'!\Q,2/&+B3_;:>D^E)4D55U,A[4=@(]8WB](7,=S06S13(<#/XZJ2ECHKJ, M),]M<@!&6C5I<5DLVY1?6J*YI%;,.([=&363G.HD5;:8;$ZPK6?=]LM59:.< MED(NDM=347)#/O(Y^:)*6KWN^1;X-%R+_/7$21OQ'PY#P_(LO[81E>(2!D== M)W[]25AZNC;)G+OEI$HR>'E^78A46#(>]D='<0IVJI] JPQ"E.L-M5#\5LUF MPH!>4MA%4@C&> 4]?GEU.!J,)TG)].+3Q\?V8*W MV^N'FF=-C8L>.:.5X)+\O4\^**41@CV2<6U%OB"VH#9YYB88]G]Y-7PSF%R0 M@LXXT7PF^!SRJ"V$(7\V5$,$R06TUTI;R*[DO=(E&0ZB/XC*R;\6%;_ND8LJ MZT^>N:%&P5#OJ'$T0\H%N:K47'+@HYZW5[ 24S!-I8#(8#PJ*D*K!6DJJQL. M>@%-.98#\U%2PI,65)*<9M"DB2HA@5GEY6X(5#SCQE"]0)&27G&8MS.F@38& MRL"4$G&-:AT%P :4PP %(')Z, M-3YJ,#DZ+V5B7L0#2 .KW7G MO:ARP!5%3H7OF6P8C EN[-BS!R$@$(LU> $#" ,+*J)EA 3GF(VI(0B9(^L> M2C02!" L%/C.36>M,KW\_>)],UVR%DP]_G9C@X, DB!^5YP(>G14O"-7<^0OL+U+)T:Z$0Y"D4I@" MQ5&LA-R!^0.?F3"95*:!?IA5M)+><;564$!#LR&[X"?&P?'>&>?74'%64"N? M &"_-!(DAF,:#0]V^9[K.CQ@_LD_"BP6*A\P.#Y!5'?BR/L5=;GW1/G:1#E, MA.O52TOX/;S8"+13A;CRF>DC)&6W,_;L@-Z8<\!%F\FRK&@T#0-+$P,%4#%*\H$D\*6 A ZZ&"4%%W<#U_?4K(W8WBIY8B[O1LTJCZ+?'U ;WMAN+56CL.6R2IME.>8:8,BR%-9R M_@VF2A44?/B>"=#/#;(+L07$8)!XX!,W?BT@^)^- /5=\#=5Y@[J]EY.2%ZH MX*E/2$XD;"5 1 #D\'0.S_DRP0$CH91:GE3,.;W"VLAO+5QUY#9%[E>,]G3Y M0<@+APK^;'1+OJ4,.AJ^3+>WHC1LI: +0 UV/#U?H!FHSDQ3@L?!<&XQ@>:V MGL,_:?$U/-S$FVO9$HSC-R]8>R98VSR\.('J*M= (3V(?.Y8#[#C?G<+(.OY MXD14,R5G'"N4BEZ&GP]U($I>UE(M.+R=%\JS(UV#,$#N4P8M$/]/*W=T?Z\Z30L<44AS7$<2XI+7A2?NE.S5FD<*'*-[E M05]#%$VZF80V5K4-_IJ0:UG#>S)D5\MS-H!WBHAX0YRZ?X#4GW>H9YA_Z MI5NV7#B6>E"R!\"DREI5AD$/8,R.R<+%H+GY/V2O3]U]LZ?_8$^M*[>8_O)ZLP_ MB/],?/?_%1JQ8^8V8?XL)NSD\&))QRG-KBXU>)Y%Z^5QY][O^HO 0UBPN[H\ M/ _6R@A_MWBMCEAK6EYDKJ&4C3QCT1QJA83.E&#!FX>'_='^,G'YMH'C(W]! MVMVX/OXO4$L#!!0 ( />(G5()3\:(B08 ,H? 8 >GEX:2TR,#(Q M,#,S,7AE>#,R9#$N:'1M[5G_;]HX%/]7?$R[MA+Y"G00&!)+J59I+5U)=;?[ MS22&6#5QYI@"]]??LY-0TG;MM-*M5ZT2)3S;[_E]_]CI_6$8PR3&24@B]#$X M_80B'B[F))$H% 1+H"ZIC%' TQ0GZ)0(01E#'P2-9@2ACNG8IFVVVX;1[P$K MOUC#$P\U+;=CN;;K(+OM-3M>HX/.3]'^9> ?Z-E'(S_XUR^#8:,,,224C_9Y5?N=S M)SQ:]WL1O4:97#/ROC;'8D830_+4:]BI[,)*"X9OS5D92QK)V'-L^VTWQ5%$ MDYG!R%1Z+3#2#4G06;RA\5PU3Q"&);TFBO<6UY 1++P)EW'WMH#[5J;ENBE/ MI#'%<\K6WIZ/&9T(NE??^TC8-9$TQ/"<@5F-C @ZW>OJZ1G]EP!OT(_1A!@Q MT?MT3*?3E60E#> R W&*VLTMXA7&F-PK-J!SDJ$SLD07?(X3$*DI2O26U&4N M9L)9!*R&JYA.J$0-UW1ZU@3LG.Y$*^<1K4((>B)NJ:76/T&S&WO>4;2Z%;== M"#; T9+/O3:LN:896()1N?9B&D4D@1W]^:;MVHUNSU(,=V:;QSQ^KVUVYW)_ M>!&<')_X@^!D= :UX&)\.3@+4#!"3AM=FF/3-]%XZ.M1I]&RZ[N,BU^L^V", M!D>C\V!X5%&\5+=C'Z+1,0H^#E^1SN/!Q8?!V7!LC/[^-/R"!GZ@='1MVWWV MA'^F]'[YV;PKQ6O]("9HD41$9! JT.QC(LADC4(B))U2DM71E LD85:Z$-"C M@!^?HC$)5:_Z\XUS:'=5$BNB'^,4 @T=-M2O0+5@E?+PK)9?)E2!B;$$3)$A MGT>DCG"&<,1310?NV0*#'I)7N:N<*5B,L9C@A&3&:,7(&@U"J494I-4135!, M,Q3B%(?@%$I!574M'_6"5G5T4D2FFA?NCOUY;R!7T(7;-%LP26EK=@"3YO, ",IZMT05)N8!T3- Q[ 3XO,BG-:=^8 M4YTY=XU7:GW7W';!+4.]3I45<*')5%4_G?TA3,!401B MD":DQ1DZ:8J@J5 M"I*IBJ&A F8,P3I@C1G4DRR%$I+5=;V8T@0GH:(#QT@?R56)4+,6+"\X/"5" M"\TVP.(&)0%/'L%:"$_8"T IJ2IEOI>[7K)4\%LZ9W[#Y!<-D\&)?@Z*PSS@ M@$!6T%P4>L4Z$@:IH RYG;RUF3^CJ[QXU^IKM;PG%!O+6X,! (GA-"->^;"] MAT,04(A7UV0JMR%W*RT)+R0O"?D-G*94VJQ]4_"+.3>P35^ZU9!N'@#7]!E9 M-Z-RGZ7ZN6F_W7=XV5]:3=-]]W;;);O5OLO-L:EU>=Q?^'>^I&MV;+?.?^'W73!;:*,!YS M8!&@1:P[Z0J!2!JA$LQ_VP@OOXY9F86"&$8S.$TGT0QC$3T '7X\'EZ^*?+K MA?L[\@\%C(K(UQ4MSQXIFR..XYINZWG-4ND,I;S*":PDOH 8RXO/]S:6EQ]) M?@PH',;JZ!R -%7VKB,_IF0*IW(%HJ#DHU%Q6Z?@]KF@@,)3@.%WQE]1%+;O MA& [O?\*H&&^>_(=P,/Q6)Y"\N;Y+(!U R0WNK7S[]MZ?2>XW.[V\0:X37!X M-1-\D41&]19NZ^5K=:#8H'MKPW8%<.8O>"N(LT+:O$U.\8P8.;;!4T"5'K[F M-"H"L=TVW>:F9>0T6R.7_"VU?NW=_P]02P,$% @ ]XB=4N>;O9&B!@ M[1H !@ !Z>7AI+3(P,C$P,S,Q>&5X,S)D,BYH=&WM67MOVS80_RJW%%T3 MP'I8=EI'S@*XCH-E:!Z+%>SQ'RU2%E&:5"DZCO?I=Z0D1T[2+MN:KAM6H+%] M/-V+OSO>48??>-Y$YD2FC,+WR=D[H"I=+I@TD&I&#%)7W.20J*(@$LZ8UEP( M>*LYG3. [\;^J$_&'C>T2&*&M?/*!E#/X@.@BB,NA .XOY!W(_@\@QVKY/Q MGN,^OA@GOUQ.*JV7UV_?G8YAQPN"GWKC(#A.CJN%OA]V(=%$EMQP)8D(@LGY M#NSDQA1Q$*Q6*W_5\Y6>!\E5D)N%Z ="J9+YU-"=HT-+P;^,T*/#!3,$TISH MDIGO=JZ3$V^ '(8;P8X.@^:SXITINCXZI/P&2K,6[+N=!=%S+CVCBK@7%F:( M3P:X?(_GUEMQ:O*X&X8OAP6AE,NY)UAFXGT,TAU)\WF^H:G*M5@S00R_859V M2VHJ&-'Q3)E\>%_!8T\6S7.9DL;+R(*+=?PJX0M6PCE;P95:$/FJ4U'PLV2: M9Z^&CKODOS$4C>X9=FL\(O@WZ;$O)BCEW9DI07)S\#"PW%_2 MTD\%<#RY2DY/3L>CY/3B'#/C:GH].D\@N8#N *[]J3_V83H9N]5N;S_L?.$H M?\KVT11&QQ>7R>1XR_#&W(/P-5R<0/+]Y"NR>3JZ>CLZGTR]BY_?37Z!T3BQ M-D9A^+GA^W&P?E%L;IF1Y R6DC)=8NRP.<%!AY>-VSOQ);3RUB\;M]_%IR>S),#1X0 M)8P591T@)1"J"DM'Z>628$2,VI9N(5.+F!(](Y*5WL6M8&L8I<:NV(WJ )>0 M\Q)24I 4P^A$2US..+IBV7Y=2W;;@5.9^K!K8QN%0T=SW[O#O0[J($Z_%?1> MJI5@>,C%GS'R6R="U/?W&^1RW %I8J^FW>T0-/_KE7NXJ4\E)\\J^*(XVO9F MWX\>>%/1'O.F6KGG#>5E(<@ZYE)PR;R94.G[+8E6:W7^13U_\%! JH32\8O0 M_1O^+>>JGU9L+)5>$#%L5XZ:U*HZ-@AH3M??Q-E])!9+/RZ)QL00:[ABA=*( M6@DG* &ZH??C)K\^5%S T%<*9T2G.?2Z'7 MU*[EJ%%;"6E@"]E2H.14+0J! M^5JU:Y9;LP]+KIGMY1[+V5VR!ZBYN[]+]S8)QM*EQI8"Q4QNL5.2V./56=8] MZ/6'F%+T_W3X/QV>G [1@W1@6*DSRVZQB*B5AG![[F#]+I>(^#I#,L)MOA2: ME1:_KKX3'#SP.;2/"$1W62"@RXX#;L8ECC"6CA*I:XHM5BW74E3P5P733FFY M.0WNCC:4J2@^>X.G'P4\_XS-V\H6_S_? :"KX^J\3ZMM00*[Q5I@#V;BXC4J M<.Z#Z* J1U]52-P49L@,NXWZP9G2V-!X"']!BI+%S9>VZM>H+Z_0:Z.Z2TLUH.^ 2 I/1M:5VX-2-G;7^;N6ZH1O' M[6:D1-2YA#-G+7&_[T=O7K9#5NMNPM<:&UO"+:PSH59-&)O?WDJ3(I[AS/[> M6V',_G 4W:R36:D$PF-HY^'['C>3/8/951]S M9^9?WP:[S__P'OP[XK]5^;J1'SUHV!KBW]RI*C&>6O2>83_&.6<9G&RZBHMZ MCK0]Q:7F2"R0>K=NZ:,T54MIT+"&_;F:RZ>'_J^) M5*%*[5X[8..N688]O$SM"G(0N;:>6'=5UB"#/W)3O!6I1RX)V]='S1Y^,M;N M4NV^PW=^]MI^=J >1-KN=F"5,R1J''HH0U_MSEE&DIE:,D6OW8V=RCKH^9QH M*ECI@F\=GS.),X]HQ]PJ\FNWH%L==E;I,T+EP)-]JI^S@4@)C>*T[H6 M#09^U-\GEX:2TR,#(Q,#,S,2YXGEX:2TR M,#(Q,#,S,5]C86PN>&UL4$L! A0#% @ ]XB=4AT29J_I&P H^,! !4 M ( !*QH 'IY>&DM,C R,3 S,S%?9&5F+GAM;%!+ 0(4 Q0 M ( />(G5)7\[AX($\ /NT! 5 " 47AI+3(P M,C$P,S,Q7VQA8BYX;6Q02P$"% ,4 " #WB)U2Z50F7]$W "2' 0 %0 M @ &:A0 >GEX:2TR,#(Q,#,S,5]P&UL4$L! A0#% M @ ]XB=4K[03P!J6 $ QZ$/ !4 ( !GKT 'IY>&DM,C R M,3 S,S%X,3!Q+FAT;5!+ 0(4 Q0 ( />(G5*8 UV:K @ &0M 8 M " 3L6 @!Z>7AI+3(P,C$P,S,Q>&5X,S%D,2YH=&U02P$"% ,4 M " #WB)U2 %)A'Z<( !%+@ & @ $='P( >GEX:2TR M,#(Q,#,S,7AE>#,Q9#(N:'1M4$L! A0#% @ ]XB=4@E/QHB)!@ RA\ M !@ ( !^B<" 'IY>&DM,C R,3 S,S%X97@S,F0Q+FAT;5!+ M 0(4 Q0 ( />(G5+GF[V1H@8 .T: 8 " ;DN @!Z M>7AI+3(P,C$P,S,Q>&5X,S)D,BYH=&U02P4& H "@"F @ D34" end